Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review

Zhi-Hua Yang1,2†, Bin Wang2†, Qian Ma1,2, Lin Wang1,2, Ya-Xin Lin2, Hai-Feng Yan1,2, Zi-Xuan Fan1,2, Hao-Jia Chen1,2, Zhao Ge1,2, Feng Zhu3, Hui-Jie Wang4, Bao-Nan Zhang4, Hai-Dong Sun5,6* and Li-Min Feng7*

1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2Tianjin University of Traditional Chinese Medicine, Tianjin, China, 3Department of Traditional Chinese Medicine, Hebei North University, Zhangjiakou, China, 4Department of Cardiology, Traditional Chinese Medicine Hospital of Tianjin Beichen District, Tianjin, China, 5Tianjin Fourth Central Hospital, Tianjin, China, 6Shenzhen Hospital Futian of Guangzhou University of Chinese Medicine, Shenzhen, China, 7Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

Coronavirus disease 2019 (COVID-19) is an emergent infectious pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is highly contagious and pathogenic. COVID-19 has rapidly swept across the world since it was first discovered in December 2019 and has drawn significant attention worldwide. During the early stages of the outbreak in China, traditional Chinese medicines (TCMs) were involved in the whole treatment process. As an indispensable part of TCM, Chinese patent medicines (CPMs) played an irreplaceable role in the prevention and treatment of this epidemic. Their use has achieved remarkable therapeutic efficacy during the period of medical observation and clinical treatment of mild, moderate, severe, and critical cases and during convalescence. In order to better propagate and make full use of the benefits of TCM in the treatment of COVID-19, this review will summarize the potential target of SARS-CoV-2 as well as the theoretical basis and clinical efficacy of recommended 22 CPMs by the National Health Commission and the Administration of TCM and local provinces or cities in the treatment of COVID-19. Additionally, the study will further analyze the drug composition, potential active ingredients, potential targets, regulated signaling pathways, and possible mechanisms for COVID-19 through anti-inflammatory and immunoregulation, antiviral, improve lung injury, antipyretic and organ protection to provide meaningful information about the clinical application of CPMs.

Keywords: COVID-19, SARS-CoV-2, traditional Chinese medicine, Chinese patent medicine, review

Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCM, traditional Chinese medicine; CPMs, Chinese patent medicines; WHO, World Health Organization; ICTV, International Committee on Taxonomy of Viruses; SARS, severe acute respiratory syndrome; MERS, Middle East respiratory syndrome; PHEIC, Public Health Emergency of International Concern; 3CLpro, 3-chymotrypsin-like protease; ACE2, angiotensin-converting enzyme 2; NSP, nonstructural proteins; ARDS, acute respiratory distress syndrome; AT2, alveolar type 2; GM-CSF, granulocyte–macrophage colony-stimulating factor; COX, cyclooxygenase; AA, arachidonic acid; IL, interleukin; IFN, interferon; C-X-C, C-X-C motif chemokine; Brd2, bromine domain containing protein 2; APN, aminopeptidase N.
INTRODUCTION

In December 2019, the first cases of unexplained viral pneumonia were reported in Wuhan, Hubei Province, China. According to the results of etiologic examinations, the pathogen that caused the disease was a novel coronavirus (Chan et al., 2020). On February 11, 2020, the novel coronavirus disease was officially named coronavirus disease 2019 (COVID-19) by the WHO (World Health Organization, 2020). On the same day, the International Committee on Taxonomy of Viruses (ICTV) gave the novel coronavirus its current name severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020). COVID-19 is an acute infectious disease caused by SARS-CoV-2 and is subsequent to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (Paules et al., 2020). It is highly infectious and is disseminating quickly worldwide. Lack of sufficient knowledge led to the rapid spread of the epidemic in the early stages. On January 30, 2020, the WHO declared the COVID-19 epidemic as a Public Health Emergency of International Concern (PHEIC) (World Health Organisation, 2020). In the subsequent months, the ongoing outbreak of COVID-19 progressed quickly and globally. The WHO defined the severity of the COVID-19 outbreak to be a global “pandemic” on March 12, 2020 (World Health Organisation, 2020). So far, COVID-19 has been mainly clinically treated by symptomatic therapies, supportive therapies, and symptom improvement, and at present, a few vaccines have been developed (Centers for Disease Control and Prevention, 2020). As one of the earliest countries to contain and tackle COVID-19, China has taken prompt and effective measures including isolation, elimination, personal protection, and treatment approaches using traditional Chinese medicine (TCM), Western medicine therapy, and a combination of the latter. In particular, in the absence of specific drugs and vaccines (Guo et al., 2020b), TCM has played an important role in the prevention and treatment of COVID-19 at various stages due to its characteristics of syndrome differentiation and treatment, integrated participation, and prevention before the disease escalates. In China, 92.58% of cases were treated by TCM, and the number of cases in which TCM participated in the clinical therapy and discharge has exceeded 70% with the proportion continuously increasing (State Administration of Traditional Chinese Medicine, 2020). The outbreak of COVID-19 has been well controlled in China for now, and TCM has contributed greatly (Xu and Zhang, 2020b). In particular, Chinese patent medicines (CPMs) have played an irreplaceable role and have provided unique advantages in the management of COVID-19. However, the underlying mechanisms of CPMs are still unclear. This review will summarize and analyze the possible active mechanisms of CPMs in the treatment of COVID-19. The findings reported may provide meaningful information for further study to investigate the mechanisms of CPMs as a therapeutic approach to overcoming COVID-19. Figure 1 shows the framework of this review.

**Figure 1** | Graphical Abstract.
In the theory of TCM, COVID-19 belongs to the category of "plague," given its feature of strong infectiousness and the resulting rapid epidemic. Exogenous pathogenic epidemic is the main etiology, and the virus target location is the lung. In addition, the basic pathogenesis is characterized by “dampness, heat, toxin, and stasis” (Chen et al., 2020a). Since ancient times, experts of TCM have accumulated rich clinical experience in the treatment of plagues. The advantage of TCM is that even if the pathogen is not clear, a set of corresponding prescriptions can be proposed based on clinical syndromes under the guidance of the theory of syndrome differentiation and treatment, which can alleviate the disease, shorten its course, and attenuate worsening or complications (Yang, 2020b). In this epidemic, TCM has exerted beneficial effects in a comprehensive way during the treatment of COVID-19. The concept of organic wholeness and the characteristics of treatment based on syndrome differentiation have contributed greatly to the therapy of COVID-19, especially in improving patients’ clinical symptoms, which is of great significance in enhancing survival rates (Li et al., 2020c).

At present, “Diagnosis and Treatment Protocol for COVID-19 (trial version 8)” formulated by the National Health Commission and the Administration of TCM and Chinese medicine prevention recommend 13 Chinese patent medicines for different stages (National Health Commission of the People’s Republic of China and National Administration of Traditional Chinese Medicine, 2020). During the medical observation period, the clinical manifestations were fatigue with gastrointestinal discomfort, and Huoxiang Zhengqi Capsule (pill, liquid, and oral liquid) was recommended. For the clinical manifestation of fatigue with fever, the recommended Chinese patent medicines are Jinhua Qinggan Granule, Lianhua Qingwen Capsule (granule), and Shufeng Jiedu Capsule (granule). During the clinical treatment period, Qingfei Paidu decoction can be used in the treatment of mild, moderate, and severe cases and can be used reasonably with the consideration of the actual conditions of critically ill patients. In addition, the corresponding prescriptions were recommended for different syndromes of mild, moderate, severe, and critical patients; Xiyanping Injection, Xuebijing Injection, Reduning Injection, Shengmai Injection, Shenfu Injection, Shenmai Injection, Tanreqing Injection, and Xingnaojing Injection are recommended for severe and critical patients. Besides, seven provincial and municipal diagnosis and treatment protocols involving nine types of CPMs were retrieved. The above 22 types of CPMs have been recommended as treatment schemes for the potential treatment of COVID-19 by using network pharmacology and molecular docking technology. The information of 22 CPMs is provided in Table 1. The details involving main findings, study design, severity classification, course of treatment, and clinical data for recommended CPMs are summarized in Table 2. Further, the relationship of CPMs and their constituents is depicted in Figure 2.
TABLE 1 | Therapeutic regimens of recommended CPMs for COVID-19 in China.

| No  | Name of Chinese patent medicines | Clinical stage                                      | Therapeutic regimen of COVID-19                                                                 | Website                                                                 |
|-----|---------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| 1   | Lianhua Qingwen Capsule         | Medical observation period                         | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 2   | Jinhua Qinggan Granules         | Medical observation period                         | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 3   | Shufeng Jiedu Capsule           | Medical observation period                         | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 4   | Huoxiang Zhengqi Oral Capsule  | Medical observation period                         | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 5   | Qingfei Paidu decoction         | Clinical treatment period—mild, moderate, severe, and critical cases | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 6   | Xiyanping Injection             | Clinical treatment period—severe case              | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 7   | Xuebijing Injection             | Clinical treatment period—severe and critical cases | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 8   | Xingnaojing Injection           | Clinical treatment period—severe and critical cases | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 9   | Reduning Injection              | Clinical treatment period—severe and critical cases | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 10  | Tanreqing Injection             | Clinical treatment period—severe and critical cases | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 11  | Shenmai Injection               | Clinical treatment period—critical case            | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 12  | Shengmai Injection              | Clinical treatment period—critical case            | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 13  | Shentu Injection                | Clinical treatment period—critical case            | National Health Commission of the People’s Republic of China. Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) | http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=0a7bdf12bd4e65bd28ca79a75e5a |
| 14  | Kangbingdu Granules             | Medical observation period; clinical treatment period—mild case | Guangdong Provincial COVID-19 TCM Therapeutic Regime (trial version II) | http://szyyj.gd.gov.cn/zwgk/content/post_2902010.html |
| 15  | Shuanghuanglian Oral Liquid     | Medical observation period; clinical treatment period—mild and moderate cases | Beijing Municipal COVID-19 TCM Preventive and Therapeutic Regime (trial version V) | http://zyj.beijing.gov.cn/sy/tzgg/202006/t202006192.html |
| 16  | Reyanning Mixture               | Clinical treatment period—mild case                | Shanxi provincial COVID-19 TCM therapeutic regime (trial version II) | http://atcm.shaanxi.gov.cn/sy/tzgg/202002/20200202_2048353.html |
| 17  | Siji Kangbingdu Mixture         | Clinical treatment period—mild case                | Shanxi Provincial COVID-19 TCM Therapeutic Regime (trial version II) | http://atcm.shaanxi.gov.cn/sy/tzgg/202002/20200202_2048353.html |

(Continued on following page)
rate, and adverse reaction rate are mainly used to evaluate the efficacy and safety of Chinese patent medicines. In addition, it also involves the disappearance rate of main symptoms, the duration of main symptoms, improvement rate of pulmonary CT, recovery rate of inflammation level, negative conversion rate of nucleic acid, and other secondary indexes. The result shows the total effective rates of LHQW (Cheng et al., 2020), HXZQ (Yang et al., 2020a), QFPD (Wang et al., 2021), and TRQ (Huang et al., 2020b) were above 85% and the treatment effect is obvious. Although the total effective rate of Xuebijing was only 68.2%, there was a significant difference compared with the control group. The adverse reaction rate and the aggravation rate were low, less than 10% (Cheng et al., 2020; Yang H. B. et al., 2020; Yu H. Y. et al., 2020; Lu et al., 2020; Wang et al., 2021), indicating that those CPMs can improve the efficacy with a good safety profile. These clinical trials found that these drugs can significantly improve the clinical symptoms caused by COVID-19. For patients of mild and moderate cases, it is necessarily important to improve the main symptoms such as fever, cough, fatigue, and expectoration, which avoid the transformation from mild to severe. CPMs contribute the most to the improvement of fever symptoms, the disappearance rate of fever is more than 80% (Duan et al., 2020), and the duration of fever was shorter in the treatment group (Cheng et al., 2020; Lu et al., 2020; Yang, 2020b). However, CPMs in relieving cough symptoms are weak, and the disappearance rate of cough is only 55% (Lu et al., 2020). By observing the improvement rate of pulmonary CT and the recovery level of inflammatory indexes, we can further know the therapeutic effect of CPMs on COVID-19. SFJD (Chen et al., 2020c), QFPD (Zeng et al., 2020), and XBJ (Zhang et al., 2020a) can significantly improve the absorption of lung CT lesions, LHQW (Cheng et al., 2020) and RYN (Yang et al., 2020c) also have this therapeutic effect, but there is no significant difference. Before and after the treatment, the difference of the oxygenation indexes and inflammatory factors such as white blood cell (WBC), lymphocytes (LYMPH), erythrocyte sedimentation rate (ESR), interleukin (IL), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and procalcitonin (PCT) was compared between the two groups, which in the treatment group was better than that in the control group (Liu K. F. et al., 2020; Qin et al., 2020; Chen et al., 2020c; Wang et al., 2021). Besides, SFJD (Qu et al., 2020), QFPD (Zeng et al., 2020), and RYN (Yang et al., 2020c) can shorten the negative conversion rate (time) of nucleic acid.

At present, the randomized controlled trials of some drugs have not been completed (such as Shengmai Injection and Bufei Huoxue Capsule) or are still in progress (such as Xiyanping Injection and Shuanghuanglian Oral Liquid), so the effectiveness of drugs in the treatment of COVID-19 cannot be determined temporarily (Wang et al., 2020a). However, because of the need for treatment, the above drugs have been widely used in the treatment of patients with COVID-19 in accordance with the strategy of "New uses of old drugs" and "Treating different diseases with the same method" in the TCM theory. The active component of the Xiyanping Injection is the total sulfonate of andrographolide, and it has the function of clearing heat and detoxification and antibacterial and anti-inflammatory and definite therapeutic effect on respiratory system diseases (Cai et al., 2020). Shuanghuanglian Oral Liquid (Zheng et al., 2020b) and Xingnaojing Injection (Xie et al., 2020) also have the function of regulating inflammatory factors and relieving inflammation reaction. This is one of the therapeutic mechanisms of COVID-19, which was treated by avoiding the cytokine storm. Shenfu Injection, Shengmai Injection, and Shenmai Injection can enhance the immune function and

**TABLE 1** (Continued) Therapeutic regimens of recommended CPMs for COVID-19 in China.

| No | Name of Chinese patent medicines | Clinical stage | Therapeutic regimen of COVID-19 | Website |
|----|---------------------------------|----------------|--------------------------------|---------|
| 18 | Qingxuan Zhike Granules         | Clinical treatment period—mild case | Hunan Provincial COVID-19 newborn infants Preventive and Therapeutic Regime (trial version I) | http://www.hnysfww.com/article.php?id = 1820 |
| 19 | Jinzhen Oral Liquid             | Clinical treatment period—mild and moderate cases | The 24th press conference on COVID-19 prevention and control held by the Information Office of Guangdong Provincial Government | http://www.gd.gov.cn/gdywdt/zwzt/yqfk/ffh/content/post_2924024.html |
| 20 | Jinye Baidu Granules            | Clinical treatment period—mild and moderate cases | TCM Diagnosis and Treatment Scheme and Preventive Scheme for Novel Coronavirus Infected Pneumonia of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology | https://www.tjh.com.cn/html/2020/0208/28991.shtml |
| 21 | Qingkailing Injection           | Clinical treatment period—severe case | TCM Diagnosis and Treatment Scheme and Preventive Scheme for Novel Coronavirus Infected Pneumonia of Tongji Hospital, Tongji Medical College, Huazhong University Of Science & Technology | https://www.tjh.com.cn/html/2020/0208/28991.shtml |
| 22 | Bufei Huoxue Capsule            | Convalescence | Guizhou Provincial COVID-19 TCM Preventive and Therapeutic Reference Regime (version II) | http://atcm.guizhou.gov.cn/xwzx/tzgg/202002/t20200219_50073831.html |
### TABLE 2 | Summary of clinical efficacy of CPMs for COVID-19.

| No | Name of Chinese patent medicines | Main findings | Study design | Severity classification | Course of treatment | Clinical data | References |
|----|----------------------------------|---------------|-------------|-------------------------|--------------------|--------------|------------|
| 1  | Lianhua Qingwen Capsule (LHQW)   | Improve clinical symptoms of fever, fatigue, cough, expectoration, shortness of breath, moist cracks, chest distress, and appetite loss. Enhance the effective rate of cardinal symptom. Reduce the proportion of normal to heavy. | Retrospective study; LHQW group: LHQW + conventional western therapy (n = 60) vs. control group: conventional western therapy (n = 38) | Medical observation period | 10 days | LHQW 86.7% vs. control 67.7%, p < 0.05 | Lu et al. (2020) |
| 2  | Jinhua Dingguan Granules (JHGD)  | Significantly reduce the clinical symptoms of fever, cough, fatigue, and expectoration. Relieve the anxiety of patients. | Randomized controlled trial; JHGD group: JHGD + conventional western therapy (n = 61) vs. control group: conventional western therapy (n = 41) | Mild | 5 days | JHGD 90.8% vs. control 30.7%, p < 0.005 | Du et al. (2020) |
| 3  | Shuang Jiedu Capsule (SJFD)      | Significantly improve the clinical symptoms, such as cough, expectoration, fatigue, chest distress, and shortness of breath. Promote the absorption of lung inflammation. Significantly shorten the symptoms improvement time and negative conversion time of the clinical. | Retrospective study; SJFD group: SJFD + arbidol hydrochloride caplet (n = 40) vs. control group: arbidol hydrochloride caplet (n = 30) | Mild and ordinary | 10 days | SJFD 7.80 vs. control 13.5%, p < 0.17 | Ou et al. (2020) |
| 4  | Huoxiang Zhiqing Oral Capsule (HZQZ) | Significantly improve clinical symptoms such as fever, cough, fatigue, and while greasy coating. Lower the rate of moderate cases worsening. Improve the clinical cure rate. | Case series; COVID-19 patients treated by HZQZ and conventional western therapy (n = 11) | Ordinary | 9–33 days | HZQZ 100% vs. control 52.7%, p < 0.01 | Yang et al. (2020a) |
| 5  | Qingfei Paidu decoction (QFPD)  | Significantly improve clinical symptoms and TCM syndromes. Improve the negative psychology and decrease risks of complications. | Randomized controlled trial QFPD group: QFPD + conventional western therapy (n = 70) vs. control group: conventional western therapy (n = 70) | Ordinary | 10 days | QFPD 89.4% vs. control 70.4%, p < 0.005 | Wang et al. (2020a) |
| 6  | Xuebijing Injection (XBJ)        | Promote the absorption of pulmonary infection. | Retrospective study; XBJ group: XBJ + conventional western therapy (n = 20) vs. control group: conventional western therapy (n = 22) | Ordinary | 7 days | XBJ 65.6% vs. control 67.7%, p < 0.05 | Zhang et al. (2020a) |
| 7  | RYM mixture (RYM)               | Improve the clinical symptoms of COVID-19 patients, such as sore throat, cough, fatigue, headache, and chest tightness. Promote the improvement of chest CT. Shorten the duration of fever and improve the novel coronavirus nucleic acid conversion rate. | Retrospective study; RYM group: RYM + conventional western therapy (n = 28) vs. control group: conventional western therapy (n = 23) | Ordinary | 7 days | RYM 79.0% vs. control 72.7%, p < 0.005 | Liu et al. (2020a) |

(Continued on following page)
hypoxia tolerance of myocardial cells, but the anti-inflammatory effect of Shengmai Injection is stronger than that of the other two (Zhang and Yang, 2008; Li et al., 2016). Early experiments in vitro antibiosis and in vivo animal studies showed (Wu et al., 2018) that Kangbingdu Granules had an antibacterial effect in vitro and antiviral, antipyretic, and anti-inflammatory effects in vivo. Liu et al. (2020b) conducted a meta-analysis for Siji Kangbingdu Mixture efficacy and safety in the treatment of children respiratory system infections. The result shows that Siji Kangbingdu Mixture can shorten the time of fever, cough, and sore throat, the efficacy effect and safety of Siji Kangbingdu Mixture were significantly better than those of ribavirin or interferon. Qingxuan Zhihe Granules in the treatment of children with upper respiratory infection (Zhang et al., 2015) and cold of wind-heat (Du et al., 2021) can effectively improve the clinical symptoms, especially for cough, sputum, and pharyngeal symptoms. Jinzheng Oral Liquid (Yu, 2019) has antipyretic, anti-inflammatory, antitussive, and antiviral pharmacological effects, and it is mainly used in the treatment of children with various respiratory diseases in clinical. Qingkailing Injection can promote the release of antipyretic substances and regulate body temperature by inhibiting endogenous pyrogen and endotoxic fever (Zhao et al., 2019). Bufei Huoxue Capsules (Zhou et al., 2020b) can improve lung ventilation function, reduce blood viscosity, and increase blood oxygen content to play a role in the treatment of chronic respiratory diseases. These drugs can improve clinical efficiency and reduce the incidence of adverse reactions in respiratory diseases (State Administration of Traditional Chinese Medicine, 2020; Xu and Zhang, 2020b). But, due to differences in usage, dosage, and application population, the adverse reactions may have new changes. So clinical trials should be completed as soon as possible (Hu and Zhang, 2020).

Figure 2 shows that Lonicera japonica Thunb, Glycyrrhiza uralensis Fisch, Scutellaria baicalensis Georgi, Gardenia jasminoides Ellis, Isatidis Radix, Forsythia suspensa Vahl, and Agastache rugosa are frequently used among all the recommended CPMs (chose only if frequency ≥4 for CPMs). These drugs are widely used in the treatment of COVID-19 for its function of clearing away heat and toxin (Chen et al., 2020b; Yu Y. R. et al., 2020). Zhou et al. (2021) suggested that Lonicera japonica Thunb extract significantly increased body weight, organ index, serum cytokines (interleukin, tumor necrosis factor, and interferon-γ), secretory immunoglobulin A (sIgA), and the activity of natural killer (NK) cells and cytokotic lymphocytes (CTL) of colitis ulcerative mouse. Besides, it can also reduce the apoptosis of splenic lymphocytes in colitis ulcerative mouse (Nomura et al., 2019). It has been found Glycyrrhizic acid can inhibit the replication of the virus and interfere with the cycle of virus adsorption and penetration. Yu et al. (2020b) indicated that Glycyrrhizic acid could inhibit the binding of RBD part of S protein and ACE2 by the MTT assay to play antiviral effect. Some researchers used Scutellaria baicalensis Georgi for antibacterial test in vitro. Some experiment results showed (Li et al., 2013) that Scutellaria baicalensis Georgi has a strong inhibitory effect on Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and other viruses. Moreover, baikalein, an active ingredient of Scutellaria baicalensis Georgi, has a strong inhibitory effect on HIV. Gardenia jasminoides Ellis is an important medicine to cure epidemic diseases. It can significantly inhibit the lung inflammation of mice induced by influenza virus, significantly reduce the mortality of mice infected by influenza virus, prolong the survival time, and reduce the level of NO in serum. It also can inhibit the cytopathy caused by H1N1, PIV-1, RSV, HSV-1, and HSV-2 in vitro (Wang et al., 2006). Isatidis Radix, with an antiviral pharmacological effect, can inhibit a variety of influenza viruses, such as H1N1, H3N2, and H9N2, and also has a good anti-inflammatory effect. It can inhibit virus-induced inflammatory response by regulating the NF-κB signaling pathway and the TLR3 signaling pathway (Huang et al., 2019). The antibacterial and antiviral effects of Forsythia suspensa were evaluated by Shi et al. (2013) in combination with the existing in vitro and in vivo studies. The

### TABLE 2 (Continued) Summary of clinical efficacy of CPMs for COVID-19.

| No | Name of Chinese patent medicines | Main findings | Study design | Severity classification | Course of treatment | Clinical data | References |
|----|----------------------------------|---------------|--------------|-------------------------|---------------------|---------------|------------|
| 8  | Jinye Baidu Granules (JYBD)      | Lower the rate of moderate and mild cases worsening | Retrospective study, JYBD group: JYBD + conventional western therapy (n = 27) vs. Control group: methylprednisolone + conventional western therapy (n = 38) | Mild and ordinary | S–7 days | • Favor: RDN 5 days vs. control 3 days, p < 0.05 | Yu et al. (2020a) |
| 9  | Reducing Injection (RDN)         | • Significantly reduce the levels of inflammatory factors | Retrospective study, RDN group: RDN + methylprednisolone (n = 21) vs. control group: methylprednisolone (n = 26) | Severe | S–7 days | • Compared with control group after treatment, the levels of WBC, IL6, IL17, and CRP in RDN group were significantly lower (p < 0.05), and the level of IL4 in group A was significantly higher (p < 0.05) | On et al. (2020) |
| 10 | Tanreqing Injection (TRQ)        | • Improve symptoms, block deterioration and promote rehabilitation | Retrospective study, TRQ group: TRQ + interferon + conventional western therapy (n = 58) vs. control group: conventional western therapy (n = 60) | All confirmed stages | 7 days | • The symptom score in the TRQ group was significantly higher (p < 0.05), • TRQ 93.1% vs. control 80.0%, p < 0.05 | Huang et al. (2020b) |

Note: Clinical data: •️; •️ disappearance rate of fever; •️ disappearance rate of cough; •️ disappearance rate of fatigue; •️ disappearance rate of other signs and symptoms; •️ the improvement rate of pulmonary CT; •️ the recovery level of inflammatory indexes; •️ the negative conversion rate (time) of nucleic acid; •️ the length of hospitalization; •️ the duration of main symptoms; •️ the anxiety level; •️ total effective rate; •️ the adverse reaction rate; •️ aggravation rate; •️ complication rate.

**Figure 2** shows that Lonicera japonica Thunb, Glycyrrhiza uralensis Fisch, Scutellaria baicalensis Georgi, Gardenia jasminoides Ellis, Isatidis Radix, Forsythia suspensa Vahl, and Agastache rugosa are frequently used among all the
study found that Forsythia suspensa has a good inhibitory effect on Escherichia coli, Staphylococcus aureus, Salmonella typhi, Escherichia coli, endotoxin, Staphylococcus epidermidis, influenza A virus, human cytomegalovirus, Japanese encephalitis virus, respiratory syncytial virus, and simple cytomegalovirus. The extract of Agastache rugosa has the ability of immunoregulation. The results showed (Chen et al., 2020d) that the volatile oil of Agastache rugosa leaves had different effects on immune cells at different times. The serum containing Agastache rugosa leaves could significantly activate the white blood cells, macrophages, and lymphocytes of mice and promote the immune function of the body.

MECHANISMS OF TRADITIONAL CHINESE MEDICINE IN THE THERAPY OF CORONAVIRUS DISEASE 2019

According to the discussion of clinical trials, the above 22 kinds of CPMs have good or potential clinical effects for the prevention and treatment of patients with COVID-19. Therefore, it is particularly important to explore the mechanism of action of CPMs for COVID-19 by computer simulation and in vivo or vitro experimental studies. We reviewed the potential mechanisms of action of CPMs and tried to find more research clues for CPMs with definite curative effect and provide theoretical support for CPMs without clinical research report. The results involving constituents, predicted active ingredients, predicted targets, and regulated signaling pathways for recommended CPMs are summarized in Table 3. The detailed mechanisms are as follows.

Chinese Patent Medicine Has Been Reported in Clinical Trials

Lianhua Qingwen Capsule has good antiviral, anti-inflammatory, and immunomodulatory effects. Ling et al. (2020) reported that Lianhua Qingwen Capsule could act on SARS-CoV-2 via multiple components, targets, and pathways. Its main ingredients kaempferol, quercetin, and luteolin have better combinations with Mpro, while indigo, glycyrrhetic acid, and stigmasterol can target the ACE2; thereby, it is possible to cure COVID-19. Li et al (2020b) found that Lianhua Qingwen Capsule could significantly inhibit the replication of SARS-CoV-2 in cells and reduce the expression of viral particles and the upregulation of inflammatory cytokines TNF-α, IL6, MCP-1, and IP-10 caused by SARS-CoV-2 infection, in a dose-dependent manner in host cells. It has a comparable antiviral potency against the SARS-CoV-2 with an IC50 value of 411.2 μg/ml. Ling et al. (2020), Li et al. (2020b), and Wang et al. (2020c) speculated that Lianhua Qingwen Capsule activity against COVID-19 was exerted through its active ingredients quercetin, luteolin, kaempferol, glycyrhizinic acid, and stigmastanol, which influenced inflammatory cytokine targets to regulate the AGE-RAGE, IL17, JAK-STAT, and TNF signaling pathways and other signaling pathways to restrain the viability of SARS-CoV-2 and improve the clinical symptoms of patients with COVID-19. New studies have proved (Li et al., 2019) that Lianhua Qingwen Capsule can effectively reduce the motility chemotaxis potential of macrophages in the acute lung injury (ALI) model and reduce the recruitment of monocyte macrophages by downregulating MCP-1. In vivo, Lianhua Qingwen Capsule can effectively inhibit the infiltration of macrophages, further reduce the edema of lung tissue, reduce the temperature fluctuation caused by ALI, and alleviate the lung pathological injury of ALI.

By using network pharmacology and molecule docking analyses, Gong et al. (2020), Shen et al. (2020), and Jimilihan et al. (2020) identified formononetin, stigmastanol, 3-methoxy-glycerol, anhydroicaritin, beta-sitosterol, crude-glycerin, glycyrrhizin B, and other key compounds from Jinhua Qinqgan Granules as having a certain degree of affinity with the SARS-CoV-2 3CL hydrolase and ACE2—which might regulate downstream TNF, IL17, PI3K/Akt, and HIF-1 signaling pathways and other signaling pathways and regulate their activity on targets such as PTGS2, HSP90AB1, HSP90AA1, PTGS1, NCOA2, AKT1, and RELA—for the prevention of COVID-19-related lung injury. Mao et al. (2020) and Lin et al. (2020) reported that the mechanism of action of Jinhua Qinqgan Granules in the treatment of COVID-19 involved multiple targets and multiple pathways related to antiviral activity, immune regulation, inflammation inhibition, and apoptosis regulation.

Cao et al. (2020) reported that 6-(3-oxoindolin-2-ylidene) indolo(2,1-b)quinazolin-12-one, bicuculline, physciondi glucoside, dihydroverticillatine, and licoisoflavone are compounds present in Shufeng Jiedu Capsule that could regulate the signaling pathways involved in human cytomegalovirus infection. Kaposi’s sarcoma-associated herpesvirus infection, the IL17 signaling pathway, and small cell lung cancer, which could be active to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2. Xu et al. (2020c) speculated that Shufeng Jiedu Capsule might regulate key targets such as IL6, IL1β, MAPK8, MAPK1, MAPK14, CCL2, CASP3, FOS, and ALB mainly through flavonoids such as quercetin, luteolin, wogonin, acacetin, isorhamnetin, 5,7,4’-trihydroxy-8-methoxyflavone, kaempferol, and phytosterol, which in turn influence the inflammatory response, oxidative stress injury, apoptosis, pulmonary fibrosis, and other processes that reduce lung injury induced by COVID-19. Furthermore, Huang et al. (2020a) and Xu et al. (2020a) reported that Shufeng Jiedu Capsule could treat COVID-19 through multiple components, multiple targets, and multiple pathways of TCM, and its potential mechanism might involve immune-inflammatory response and antiviral activity. Its active ingredients have the potential to help people resist infection by SARS-CoV-2 as they interfere with the binding of SARS-CoV-2 to ACE2. Liu et al. (2016) suggested that Shufeng Jiedu Capsule has a significant antipyretic effect, which could reduce the levels of PGE2, TNF-α, IL1α, IL6, and IL1β, reduce the heat production, and increase the content of AVP.

Also using molecule docking analyses, Deng et al. (2020) found that the core compounds in Huoxiang Zhengqi Oral Liquid such as quercetin, isorhamnetin, isorislidon, kaempferol, wogonin, and baicalein were similar in affinity to currently recommended drugs for the treatment of COVID-19 such as remdesivir, ribavirin, and ritonavir. Of these, isorhamnetin, quercetin, and isorislidon had
the strongest affinity. These compounds may interfere with ACE2 binding to PTGS2, HSP90AB1, AR, CAMSAP2, and other targets that regulate multiple signaling pathways and thus exert a preventive or therapeutic effect on COVID-19. Du et al. (2020) reported that elicorice glycoside E, naringenin, robinin, [(2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one], and kaempferol strongly bind to 3CL protease and have been proposed as potential inhibitors of 3CL protease. Furthermore, the antiviral pathway of Huoxiang Zhengqi might be exerted through the PI3K-Akt signaling pathway and its downstream effects on viral replication.

Zhao et al. (2021) analyzed the treatment mechanism of Qingfei Paidu decoction from molecular, pathway, and network levels and conducted in vitro experiments to verify. The result showed that the main constituent of Qingfei Paidu decoction—baicalin—can suppress NF-κB signaling and downregulate the expression of IL6 and TNF-α and CCL2 in macrophage-like cell line RAQ264.7. In addition, Qingfei Paidu decoction can inhibit the activity of PTGS2 and PGE2 production in order to exhibit the effects of immune regulation and regulate ribosomal proteins related to the viral replication so that it inhibited the growth and production of virus.

In the clinical treatment of patients with COVID-19, Xuebijing Injection mainly inhibited IL6, TNF-α, MCP1, mip2, and IL10 to inhibit inflammatory response (Huang et al., 2020a). Xuebijing Injection could inhibit respiratory viruses while relieving inflammation, delay pathological changes in the lungs, and protect from liver damage caused by viruses or antiviral drugs. It can reduce the apoptosis of tubular cells during sepsis, improve the expression of apoptosis-related proteins Bcl-2 and Bax, and alleviate kidney injury (Sun et al., 2017). It could also inhibit bacterial infections, improve body immunity, and reduce cardiovascular damage (Kang, 2020; Shi X. et al., 2020). Zheng et al. (2020a) reported that hyperoside, salvianolic acid C, salvianolic acid A, cymarinose, salvianolic acid B, and paeoniflorin were the main components of Xuebijing Injection and had a good affinity with SARS-CoV-2 3CL hydrolase and its human receptor, ACE2. Two mechanisms were potentially involved in Xuebijing treatment of SARS-CoV-2-induced pneumonia. First, its main activity could be mainly exerted through the regulation of the human immune-inflammatory response to protect important organs, and second, Xuebijing Injection might also act on the essential proteins of the virus, 3CLpro and ACE2, to induce antiviral effects. Xuebijing Injection presents the characteristics of multiple components and activity against multiple targets and pathways in treating COVID-19, based on its overall synergy (Kong et al., 2020a; He et al., 2020). Chen et al. (2018) showed that 18 ml/kg Xuebijing Injection could stimulate Treg differentiation and moderately inhibit Th17 differentiation, effectively prevent neutrophil infiltration into lung and kidney, and improve its survival rate in this septic shock model.
TABLE 3 | Summary of potential action mechanisms of CPMs for COVID-19.

| No | Name of Chinese patent medicine | Latin name of composition | Chinese name of composition | Predicted active ingredient | Predicted target | Regulated signaling pathways | References |
|----|----------------------------------|--------------------------|---------------------------|---------------------------|------------------|----------------------------|------------|
| 1  | Lianhua Qingwen Capsule          | Ephedra sinica Stapf, Rheum palmatum L., Lonicera japonica Thunb, Mentha canadensis L., Glycyrrhiza glabra L., Rhodiola rosea L., Hojilla crenulata (Hook.f. & Thomson) | Mahuang, Dahuang, Jinynihua, Bohe, Gancao, Hongqingshan, Guanzhong, Shigao, Huoxiang, Kuixingren, Yinxingcao, Lianqiao, Bartangen | Kaempferol, quercetin, luteolin, glycyrrhetinic acid, indigo, β-sitosterol, etc. | PTGS2, IL6, CASP3, MAPK1, EGFR, ACE2, TNF, IL1B, MAPK8, CCL2, IL10, IL2, IFNγ, etc. | AGE-RAGE signaling pathway, IL17 signaling pathway, JAK-STAT signaling pathway, TNF signaling pathway | Ling et al. (2020); Wang et al.,(2020c); Wang et al. (2020g) |
| 2  | Jinhua Qinggan Granules          | Lonicera japonica Thunb, Artemisia annua L., Arctium lappa L., Scutellaria baicalensis Georgii, Fritillaria thunbergii Miq. | Qinghao, Jinyinhua, Niubangzi, Huangqin, Zhebeimu | Quercetin, kaempferol, naringenin, isorhamnetin, forononin, 7-methoxy-2-methyl, β-sitosterol, isoflavone, licochalcone B, glycospyrin C, licochalcone a, 3’-methoxyglabridin, arachidonic acid, stigmastanol, etc. | AKT1, RELA, PTGS2, HSV90A1, HSV90A1, PTGS1, NOS2, ESR1, etc. | TNF signaling pathway, IL17 signaling pathway, P3K-Akt signaling pathway, HIF-1 signaling pathway | Shen et al. (2020); Jimllian et al. (2020) |
| 3  | Shufeng Jiedu Capsule            | Glycyrrhiza glabra L., Foryonh suspena (Thunb.) Veil, Isatis tinctoria L., Reynoutria japonica Houtt, Patinia scabiosaolia Link, Phragmites australis (Cav.) Trin. ex Steud., Vertebra officinalis L., Bupleurum chinense DC. | Huzhang, Baijiangcao, Lianqiao, Lugun, Maliancao, Chaihu, Bartangen, Gancao | Quercetin, 6-(3-oxindolin-2-ylidene) indole (2,1-b), β-sitosterol, kaempferol, luteolin, quinonazolin-12-one, bicusculine, isorhamnetin, physciondiglucoside, dihydroverticillatine, isoellagitannin, 5,7,4’-trihydroxy-8-methoxyflavone, acacetin, maslinic acid, etc. | PTGS2, ESR1, AR, NOS2, PTGS1, NOS2, F10, ALB, PPARα, PRS5, SCNS5, IL6, IL1B, FOS, CCL2, MAPK8, MAPK1, MAPK14, CASP3, etc. | Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, IL17 signaling pathway, small-cell lung cancer | Cao et al. (2020); Xu et al. (2020) |
| 4  | Huoxiang Zhengqi Oral Liquid     | Glycyrrhiza glabra L., Magnolia officinalis Rehder & E.H.Wilson, Perilla frutescens (L.) Britton, Areca catechu L., Simalax glabra Roxb, Atractylodes lancea (Thunb.) DC., Paonia lactiflora Pall, Citrus × aurantium L., Pinella ternata (Thunb.) Makino, Pogostemon cablin (Blanco) Benth. | Houpu, Banxia, Zisu, Dafuli, Fuling, Cangzh, Baishao, Chenpi, Gancao, Huoxiang | Quercetin, isorhamnetin, ursodiol, kaempferol, wogonin, baicalein | PTGS2, HSV90A1, AR, CAMSA, PPAR, NOS2, etc. | TNF signaling pathway, HIF-1 signaling pathway, signaling pathway, toxoplasmomiasis, bladder cancer, prostate cancer, pancreatic cancer, pathways in cancer | Deng et al. (2020) |
| 5  | Qingfei Paidu decoction          | Ephedra sinica Stapf, Glycyrrhiza glabra L., Gypsum Fibrosus, Scutellaria baicalensis Georgii, Bupleurum chinense DC., Simalax glabra Roxb, Citrus × aurantium L., Pogostemon cablin (Blanco) Benth., Neolitsea cades (L.) Kosterm, Alisma plantago-aquatica subsp. orientale Sam, Polygonum umbellatus (Pers.) Fr., Atractylodes macrocephala Koelz, Pinella ternata (Thunb.) Makino, Zingiber officinale Roscoee, Aster tataricus Lf., Tussilago farfara L., Polygonum aviculare L., Asarum sieboldii Miq., Dioscorea oppositifolia L., Prunus armeniaca L. | Mahuang, Gancao, Xingren, Shigao, Guzhi, Zexi, zhuang, Baizhu, Fuling, Chaihu, Huangqin, Banxia, Shengjiang, Ziwan, Donghux, Shexian, Xian, Shanxiao, Zhichi, Chenpi, Huoxiang | Baicalin, Glycyrrhizic acid, hesperidin, hyperoside | AKT1, TNF-α, IL6, PTGS2, HMOX1, IL10, TPS3 | NOD-like receptor signaling, Toll-like receptor signaling, cytokine-cytokine receptor interaction, chemokine signaling, Th1 cell differentiation, IL17 signaling pathway, NF-kappa B signaling pathway, TNF signaling pathway, necroptosis, apoptosis, HIF-1 signaling pathway, mitochondrial | Zhao et al. (2021) |

(Continued on following page)
| No | Name of Chinese patent medicine | Latin name of composition | Chinese name of composition | Predicted active ingredient | Predicted target | Regulated signaling pathways | References |
|---|---|---|---|---|---|---|---|
| 6 | Xiyanping Injection | Andrographolide sulfonates. | Andrographolide sulfonates | Andrographolide | COX-2, IL-1β, TNF, MAPK1, MAPK4, MAPK8, MAPK14, etc. | — | Cai et al. (2020) |
| 7 | Xuebijing Injection | Conioselinum anthriscoides, Carthamus tinctorius L., Angelica sinensis (Olk.) Dets, Paeonia veitchii Lynch, Salvia miltiorrhiza Bunge. | Chishao, Danggui, Honghua, Danshen, Chuanxiong | Quercetin, kaempferol, rosmaninic acid, rutin, kaempferol, chlorogenic acid, tanshinone II A, hydroxysafflor yellow A, paconiforin | TNF, MAPK1, IL-2, IL-6, IL-10, etc. | IL-17 signaling pathway, hepatitis C, hepatitis B, toxoplasmosis | Xie et al. (2020) |
| 8 | Xuebijing Injection | Moschus berezovskii Flerov, Dryobalanops aromatica | Shexiang, Yujin, Bingqian, Zhizhi | Chitinogen, kaempferol | PARP1, PTGS2, MMP9, CDK2, ADORA2A, ALCX5, GSK3B, etc. | — | — |
| 9 | Reducing Injection | Chishao, Danggui, Honghua, Quercetin, gallic acid, luteolin, rosmarinic acid, PTGS2, PTGS1, CASP3, RELA | MAPK4, MAPK8, MAPK14, etc. | MAPK3, TP53, EGFR, CASP3, MAPK1, MAPK8, IL-6, CASP8, CASP3, IL-1B, STAT1, TNF, CCL2, etc. | — | AGE-RAGE signaling pathway, human cytomegalovirus infection, TNF signaling pathway, IL-17 signaling pathway | Pu et al. (2020); Gao et al. (2020); Shen et al. (2020e) |
| 10 | Tanreqing Injection | Carthamus tinctorius L., Angelica sinensis (Oliv.) Diels, Paeonia veitchii | Zhizi, Qinghao, Jinyinhua | Apigenin, quercetin, kaempferol, luteolin, stigmastanol, β-sitosterol, isorhamnetin, chrysoeriol | RELA, MAPK1, MAPK14, MAPK8, IL-6, CASP8, CASP3, IL-1B, STAT1, TNF, CCL2, etc. | — | — |
| 11 | Shenmai Injection | Lonicera japonica Thunb, Artemisia annua L., Gardenia jasminoides | Pu et al. (2020); Gao et al. (2020); Chen et al. (2020) |
| 12 | Shengmai Injection | Ophiopogon japonicus (Thunb.) Ker Gawl., Talinum paniculatum (Jacq.) Gaertn. | Hongshen, Maidong | Ophiopogonin D, ophiopogonin D, ginsenoside Rg 2, methyl ophiopogonane A, ginsenoside Rb2, ginsenoside Rf0, ophiopogon A, sanchinoside rd, ophiopogonane E, ginsenoside re, etc. | IL-6, GADPH, ALB, TNF, MAPK1, MAPK3, TP53, EGFR, CASP3, CCL2.8 | — | HIF-1 signaling pathway, TNF signaling pathway, spongolipid signaling pathway, toll-like signaling pathway, neurotrophin signaling pathway | Han et al. (2020) |
| 13 | Shengmai Injection | Ophiopogon japonicus (Thunb.) Ker Gawl., Schisandra chinensis (Turcz.) Baill., Talinum paniculatum (Jacq.) Gaertn. | Maidong, Hongshen, Wuweizi | Schisanthine, stigmasterol, N-trans-feruloyltyramine, β-sitosterol, angeloylgomisin O, gomisin-A, gomisin-R, chroanginic acid, kadsulignan B, etc. | CASP3, CASP8, PTGS2, BCL2, BAX, PRKCA, PTGS1, PIK3CG, F10, NOS3, DPP4, NOS2, TLR9, ACE, PTGS2, PTGS1, BCL2, etc. | — | AGE-RAGE signaling pathway, pS3 signaling pathway, small-cell lung cancer, apoptosis | Wang et al. (2020d); Wang et al. (2020c) |
| 14 | Kangbingdu Granules | Lonicera japonica Thunb, Forsythia suspensa (Thunb.) Vahl, Scutellaria baicalensis Georgi. | Lianqiao, Huangqin, Jinyinhua | Quercetin, β-sitosterol, luteolin, kaempferol, neobaicalein, dihydrooroxylin A | CASP3, TP53, MAPK8, IL-6, MAPK1, MAPK1, CCL2, etc. | — | AGE-RAGE signaling pathway, IL-17 signaling pathway, C-type lectin receptor, HIF-1 signaling pathway | Li et al. (2020); Wang et al. (2020c) |
| 15 | Shuanghuanglian Oral Liquid | Lonicera japonica Thunb, Forsythia suspensa (Thunb.) Vahl, Scutellaria baicalensis Georgi. | Lianqiao, Huangqin, Jinyinhua | Quercetin, β-sitosterol, luteolin, stigmastanol, kaempferol, neobaicalein, dihydrooroxylin A | CASP3, TP53, MAPK8, IL-6, MAPK1, MAPK1, CCL2, etc. | — | HIF-1 signaling pathway, TNF signaling pathway, pathway in cancer, tuberculosis, hepatitis C, pertussis, salmonella infection, influenza A, herpes simplex virus infection | Zheng et al. (2020b); Chen et al. (2020b) |

(Continued on following page)
| No. | Name of Chinese patent medicine | Latin name of composition | Chinese name of composition | Predicted active ingredient | Predicted target | Regulated signaling pathways | References |
|-----|--------------------------------|--------------------------|----------------------------|---------------------------|-----------------|----------------------------|------------|
| 16  | Reyanning Oral Liquid         | Reynoutria japonica Houtt, Patrinia scabiosifolia Link, Taraxacum mongolicum Hand.-Mazz., Scutellaria barbata D. Don. | Pugongying, Banzhilian, Huazhang, Baijiangcao | Apigenin, chrysin-5-methylether, catechin, 7,2′-dihydroxy-5,8-dime thoxy-2-phenylchromone, 5,7-dihydroxy-8-methoxy-2-(2-methoxyphenyl)chromone, etc. | CCL2, CD40LG, CXCL10, CXCL8, IFNG, IL10, IL13, IL1B, IL2, IL6, etc. | IL17 signaling pathway, cytokine-cytokine receptor interaction pathway | Wang et al. (2020e) |
| 17  | Siji Kangbingdu Mixture       | Mentha canadensis L., Glycyrrhiza glabra L., Prunus armeniaca L., Houttuynia cordata Thumb, Forsythia suspensa (Thunb.) Vahl, Phragmites australis (Cav.) Trin. ex Steud., Perilla frutescens (L.) Britton, Morus alba L., Chrysanthemum × morifolium (Ramat.) Hemsl., Platycodon grandiflorus (Jacq.) A.DC., Nepeta cataria L. | Sangye, Zisu, Juhua, Lugeng, Jinying, Pugongying, Ganciao, Bohe, Lianqiao, Jiegeng | Quercetin, kaempferol, luteolin, rutin, naringenin | PTGS1, ADRB2, JUN, IL6, IL1B, IL10, IFNG, ACHE, IL2, etc. | IL17 signaling pathway, cytokine-cytokine receptor interaction, viral protein interaction with cytokine and cytokine receptor, arachidonic acid metabolism | Liu et al. (2020b) |
| 18  | Qingxuan Zhike Granules       | Mentha canadensis L., Glycyrrhiza glabra L., Prunus armeniaca L., Paeonia lactiflora Pall, Citrus × aurantium L., Aster tataricus L.f., Morus alba L., Platycodon grandiflorus (Jacq.) A.DC., Nepeta cataria L. | Kuxingren, Chenpi, Baishao, Ziwan, Sangye, Ganciao, Bohe, Jiegeng, Zhiqiao | Quercetin, kaempferol, 7-methoxy-2-methyl, formononetin, etc. | PTGS2, ESP1, HSP90AA1, CALM1, AR, etc. | Small cell lung cancer, non-small-cell lung cancer, T-cell receptor signaling pathway | Zong et al. (2020) |
| 19  | Jizhen Oral Liquid            | Ephedra sinica Stapf, Rheum palmatum L., Lonicera japonica Thunb, Scutellaria baicalensis Georgi, Saiga tatarica Linnaeus, Laps Chilini, Bovis Calculus Arth Actus, Fritillaria cirrhosa D.Don. | Mengxi, Chuanbeimu, Lingyangjiao, Pengongruhuang, Huangqin, Jinyinhua, Dahuang, Muhuang | Isoglaborolide, glaborolide, ebiededrine, desoxo-glaborlidelactate, preimine, verticinone, imperine, ussurenedrine, euchrenone A5, quercetin, kaempferol, naringenin, baicalen, etc. | mTOR, JAK3, ACE2, TNF-α, AKT2, PIKCA, MEK1, BRD2, ACE, ANPEP, MAPK3, MAPK8, IL6, CASP3, IL10, MAPK1, OXO3, CCL2, etc. | PI3K-Akt signaling pathway, Jak-STAT signaling pathway, TNF signaling pathway, MAPK signaling pathway | Tao et al. (2020) |
| 20  | Jinye Badu Granules           | Lonicera japonica Thunb, Houttuynia cordata Thumb, Taraxacum mongolicum Hand.-Mazz., Isatis tinctoria L. | Daqingye, Pugongying, Yuxingcao, Jinyinhua | Quercetin, glycyrol, indirubin, etc. | TNF, IL1, IL6, IL1B, PTGS2, PTGS1, NOS3, PPARG, etc. | — | Shi et al. (2020a) |
| 21  | Qingkailing Injection         | Lonicera japonica Thunb, Isatis tinctoria L., Scutellaria baicalensis Georgi, Gardenia jasminoides J.Ellis, Cornu Margaritifera, Cornu Bubali. | Shuiniujiao, Zhenzhumu, Jinyinhua, Zhizi, Banlangen, Huangqin | Acacetin, syringin, kaempferol, quercetin, emodin, luteolin, apigenin, etc. | CASP3, CASP8, FASLG, EGFR, CYCS, EGF, BCL2, IL4, PPARG, MCL1, etc. | TNF signaling pathway, Fc epsilon RI, PI3K-Akt signaling pathway | Zhang et al. (2020c) |
| 22  | Buifei Huoxue Capsule          | Paeonia veitchii Lynch, Astragalus mongholicus Bunge, Cullen coryloifolium L., Medik. | Huangqi, Buguzhi, Chishao | Quercetin, kaempferol, baicalen, 7-O-methylsimonurulatol, formononetin, 7-iso-steril, stigmasteral, isorhamnetin, ellagic acid, 3,9-di-O-methylissoxolin, etc. | IL6, MAPK8, PTGS2, PTGS1, NCOA3, NOS2, RELA, CXCL8, IL10, MAPK1, FOS, CASP3, MAPK14, IRF1, IL1B, CD14, IL1A, etc. | Pertussis, Chagas disease, TNF signaling pathway, Salmonella infection, tuberculosis | Guo et al. (2020a) |
Reyanning Mixture is recommended by the Diagnosis and Treatment Protocol for COVID-19 (trial version 2) statement issued by the Shanxi Province for the therapy of clinically mild and severe cases. Reyanning Mixture exerted beneficial effects in treating coronavirus pneumonia mice by its activity on the lungs. The result showed that Reyanning Mixture can reduce the lung index of coronavirus pneumonia mice with pestilence attacking the lung, significantly increase the percentage of CD8\(^{+}\) T and CD4\(^{+}\) T lymphocytes in peripheral blood of model mice, increase the percentage of total B lymphocytes, reduce virus load in lung tissue, reduce the levels of TNF-α, IFN-γ, IL6, and IL10 in the lung tissue, and reduce the content of motilin in the serum of model mice. It manifested obvious therapeutic effects by improving lung lesions, enhancing gastrointestinal function, improving autoimmune function, and reducing the expression of inflammatory factors in vivo, which provide a rationale for future clinical applications of the active compounds (Bao et al., 2020). Wang et al. (2020e) reported that the core compounds in Reyanning Mixture such as apigenin, chrysins-5-methylether, and catechin act on CD40LG, CXCL10, CXCL8, IL10, IL2, IL6, and other targets involved in the IL17 signaling pathway and cytokine–cytokine receptor interaction pathway.

Jinye Baidu Granules are suitable for the treatment of viral pneumonia, acute upper respiratory tract infection, influenza, and other viral and bacterial diseases. It has been used for the prevention and control of SARS virus infection during the SARS outbreak in 2003 and achieved good results. At present, it has been listed as a reserved drug for the prevention and control of COVID-19 in Hubei, Guangdong, Hebei, Fujian, and Anhui Provinces. In the presence of a cytokine storm causing DIC, sepsis, Jinye Baidu Granules particles exert a protective effect on liver microsomal activity, calcium homeostasis, in addition to resisting free radical production and activity, and reducing levels of circulating or tissue inflammatory cytokines (such as TNF-α, IL1, IL6, and IL8) and inhibiting dysregulated TNF-α release, which lead to the reduction of vascular endothelial cells and organ damage and prevention of the activation of the blood coagulation system (Shi et al., 2020a).

Pu et al. (2020), Gao et al. (2020), and Chen et al. (2020e) reported that Reduning Injection might act on targets such as inflammatory cytokines and MAPKs through its active ingredients quercetin, kaempferol, beta-sitosterol, luteolin, isorhamnetin, and chrysoeriol, to regulate the AGE-RAGE, human cytomegalovirus infection, TNF, and IL17 signaling pathways and to treat COVID-19 patients. In addition, the antipyretic mechanism of Reduning Injection is related to inflammatory mediators such as IL1, ET-1, IL6, and PGE 2 and regulating endogenous pyrogen (Wang et al., 2013).

Kong et al. (2020b) showed that kaempferol, quercetin, baicailein, luteolin, and wogonin, which are the active compounds of Tanreqing Injection, showed good affinity toward SARS-CoV-2 3CL hydrolase. The molecular mechanism of Tanreqing Injection in the treatment of COVID-19 involved the synergistic features of multiple components, targets, and pathways of TCM.

Chinese Patent Medicines with Potential Therapeutic Effect

Cai et al. (2020) reported andrographolide, a main component of Xiyangping Injection, had potential antiviral effects in the treatment of COVID-19. It could reduce the level of inflammation in patients, improve respiratory symptoms, inhibit concurrent bacterial infection, and improve the immune response. The research showed (Yang and Luo, 2017) that andrographolide can reduce the level of Th17 and Th2 type cells and play an immunomodulatory role. At the same time, it would not induce similar immunosuppressive effects of steroids, and the incidence of adverse reactions was low. Andrographis paniculata Nees, which has the same active ingredient as Xiyangping Injection, can inhibit LPS-induced hyperthermia in rabbits by reducing the levels of 5-HT and increasing the levels of cAMP in the brain (Xu et al., 2019). In addition, andrographolide can reduce the inflammatory damage of the liver by downregulating NF-κB signaling pathway to reduce the expression of inflammatory factors, including TNF-α and IL6.

Xie et al. (2020) discovered the core compounds in Xingnaoqing Injection including chlorogenin, 3-methylkempferol, kaempferol, morin, 5-hydroxy-6,7,3′,4′,5′-pentamethoxyflavone, gardenin, quercetin, dryobalanone, artemisetin, genistein, curcumin, and elemicin. These compounds might interfere with various signaling pathways by acting on the key targets, such as PARP1, PTGS2, MMP9, CDK2, ADORA2A, ALOX5, and GSK3B. They may also regulate the inflammatory response, apoptosis, oxidative stress, angiogenesis, and the other processes to alleviate the neurological damage sometimes caused by SARS-CoV-2. Further, they inhibited viral replication and prevented infection of the host cell by binding with Mpro, and the ACE2 complex. These activities implied that Xingnaoqing Injection might have a positive therapeutic effect on the neurological damage caused by SARS-CoV-2.

Shenfu Injection, Shenmai Injection, and Shengmai Injection are recommended for severe patients, which have a good role in relieving cytokine storm. Their main components are similar, which can inhibit inflammatory factors and alleviate cytokine storm. Han et al. (2020) claimed that ophiopogonin D\(^{1}\), ophiopogonin D, ginsenoside Rg2, ophiopogon A, methyl ophiopogonanone A, ophiopogonin-3-O-1-L-rhamnopyranosyl, ginsenoside Rb2 (1→2)-β-D-glucopyranoside, ginsenoside R0, sanchinioside Rd, ophiopogonanone E, and ginsenoside Re in Shenmai Injection showed a higher binding affinity with 3CL hydrolase. These compounds were the main effective components in the treatment of COVID-19 combined with coronary heart disease. Shenmai Injection could achieve simultaneous intervention of COVID-19 and coronary heart disease by inhibiting cytokine storms, maintaining cardiac function homeostasis, and regulating immunity and antiviral activity. It exerted a mutual influence and complex interference on a network regulatory mechanism. Fang et al. (2012) reported that Shenmai Injection could cut down the expression of TNF-α and ICAM-1 to play a protective role against lung injury. Li et al. (2020d) reported that kaempferol, ginsenoside Rh2, beta-sitosterol, stigmastrol, and deoxyandrographolide might be the main active ingredients in Shenfu Injection which cause inhibition of the SARS-CoV-2 3CL hydrolase activity and regulate ACE2. As a result, the antiviral effects, immunoregulation, and targeting of the cytokine storm by
Shenfu decoction may play an important role in the treatment of critically ill patients with COVID-19 through regulating multiple signaling pathways including the AGE-RAGE signaling pathway in diabetic complications, IL17, C-type lectin receptor, and HIF-1 signaling pathways. Shenfu Injection also can reduce the seriousness of lung injury (Wang et al., 2020b). Wang et al. (2020d) found that the active compounds in Shengmai Injection, such as schisanlactone E, N-trans-feruloyltyramine, and stigmasterol, could act on CASP3, PTGS2, NOS2, NOS3, and other targets to regulate multiple signaling pathways to induce anti-inflammatory effect, immune regulation, and antishock and increase blood oxygen saturation in the treatment of COVID-19. Shengmai Injection could reduce the levels of iNOS and NF-kB, improve the peroxidation damage, and has a protective effect on acute lung in rats (Liu et al., 2009).

Kangbingdu Granules had a significant role in combating the SARS virus in 2003 and the influenza A (H1N1) virus in 2009, and thus, the formulation was recommended for pediatric prophylaxis and for adults with fever or cough and sore throat during medical diagnosis and treatment of COVID-19 in Guangdong Province. Yao et al. (2020) reported that the core active compounds such as bicuculline, luteolin, and quercetin in

### TABLE 4  | The pharmacological action of CPMs for the treatment of COVID-19.

| Category                          | Name                        | Anti-inflammatory and immunoregulation | Antiviral | Improving lung injury | Antipyretic | Organ protection | Reference                                      |
|-----------------------------------|-----------------------------|---------------------------------------|-----------|-----------------------|-------------|------------------|------------------------------------------------|
| Clinical efficacy has been reported | Lianhua Qingwen Capsule    | ++                                    | ++        | ++                    | –           | –                | (Li et al., 2020b); (Li et al., 2019)          |
|                                   | Jinhua Qinggan Granules    | ++                                    | ++        | –                     | –           | –                | (Shen et al., 2020); (Jimilihan et al., 2020) |
|                                   | Shufeng Jiedu Capsule      | ++                                    | ++        | –                     | +           | –                | (Cao et al., 2020); (Xu et al., 2020c); (Lu et al., 2018) |
|                                   | Huoxiang Zhengqi Oral Liquid | ++                                    | –         | –                     | –           | –                | (Deng et al., 2020); (Du et al., 2020)         |
|                                   | Qingfei Paidu decoction    | ++                                    | –         | –                     | –           | –                | (Zhao et al., 2021)                           |
|                                   | Xuebijing Injection        | ++                                    | ++        | –                     | –           | –                | (Zheng et al., 2020a); (Chen et al., 2018); (Huang et al., 2020a) |
|                                   | Reyanning Oral Liquid      | ++                                    | –         | ++                    | –           | –                | (Rao et al., 2020); (Wang et al., 2020a)       |
|                                   | Jinye Baidu Granules       | ++                                    | –         | –                     | –           | +                | (Shi et al., 2020a)                           |
|                                   | Shenfu Injection           | ++                                    | –         | –                     | –           | –                | (Han et al., 2020); (Fang et al., 2012)        |
|                                   | Shengmai Injection         | ++                                    | –         | –                     | –           | –                | (Wang et al., 2020d); (Liu et al., 2009)       |
|                                   | Shenfu Injection           | ++                                    | ++        | ++                    | –           | –                | (Li et al., 2020d); (Wang et al., 2020b)       |
|                                   | Kangbingdu Granules        | ++                                    | –         | –                     | –           | –                | (Yao et al., 2020)                            |
|                                   | Shuang Huanglan Oral Liquid | ++                                    | –         | –                     | +           | –                | (Zheng et al., 2020b); (Wang et al., 2020a); (Liang and Zhou, 2011) |
|                                   | Siji Kangbingdu Mixture    | ++                                    | –         | –                     | –           | –                | (Liu et al., 2020b)                           |
|                                   | Qingxuan Zhike Granules    | ++                                    | –         | –                     | –           | –                | (Jiao, 2020); (Zong et al., 2020)              |
|                                   | Jinzheng Oral Liquid       | ++                                    | –         | ++                    | –           | –                | (Tao et al., 2020); (Hong et al., 2021); (Kao et al., 2009) |
|                                   | Qingkailing Injection      | ++                                    | –         | –                     | +           | +                | (Zheng et al., 2020c); (Jao et al., 2013); (Sun et al., 2005) |
|                                   | Bufei Huoxue Capsule       | ++                                    | –         | –                     | –           | –                | (Jing et al., 2017); (Guo et al., 2020a)       |

++: has corresponding pharmacological actions
Kangbingdu Granules showed good affinity to SARS-CoV-2 3CL protease. They could interact with ACE2 via its targets PTGS2, HSP90AB1, and PTGS1 to regulate multiple signaling pathways, thereby exerting therapeutic effects on COVID-19.

Shuanghuanglian Oral Liquid is recommended by the Diagnosis and Treatment Protocol for COVID-19 in Beijing. Recent studies have revealed that Shuanghuanglian Oral Liquid has broad-spectrum antiviral and antibacterial activities, which can improve the immune response of the human body. It is an effective broad-spectrum antiviral agent. Zheng et al. (2020b) reported that the mechanism of Shuanghuanglian Oral Liquid against COVID-19 involved its active compounds including quercetin, stigmasterol, beta-sitosterol, kaempferol, neobaicalein, dihydrooroxylin A, and luteolin. These compounds might regulate related biological processes and signaling pathways by acting on key proteins involved in protein network interaction such as CASP3, TP53, MAPK8, IL6, and CCL2. The research showed that Shuanghuanglian Oral Liquid has a protective effect against acute liver failure in mice, which is mainly reflected in improving liver function, inhibiting cytokine synthesis, and reducing inflammatory injury (Wang et al., 2020f). Shuanghuanglian Oral Liquid also can inhibit the LPS-induced increase of body temperature in rats (Liang and Zhou, 2011).

The Siji Kangbingdu Mixture is a CPM recommended by the Diagnosis and Treatment Protocol for COVID-19 (trial version 2) in Shanxi Province and is applicable to mild and severe cases. Liu et al. (2020b) indicated that Siji Kangbingdu Mixture exhibited the potential to be an outstanding agent with better effectiveness and safety compared to chemical antiviral agents and predicted that the Siji Kangbingdu Mixture treatment presented a “win-win” mechanism because it was beneficial not only to symptom alleviation but also for disease resolution. The mechanism might be related to the IL17 signaling pathway and the regulation of the arachidonic acid metabolism pathway which is active in the systemic immune response and inflammation and may also interfere with SARS-CoV-2 replication by inhibiting 3CL protease.

Qingxuan Zhike Granule is recommended for COVID-19 patients with mild and moderate disease in Hunan Province, where special TCM treatment protocols for children have been introduced. Experimental studies (Ruan et al., 2010; Qiao, 2020) have shown that Qingxuan Zhike Granules including quercetin, kaempferol, and luteolin had a similar affinity with SARS-CoV-2 3CL protease as the recommended drugs. The active ingredients in Qingxuan Zhike Granules might regulate multiple signaling pathways by acting on targets such as PTGS2, HSP90AA1, and ESR1, thereby ameliorating disease progression.

Jinzhen Oral Liquid is mainly used to treat children with bronchitis, bronchopneumonia, mycoplasma pneumonia, and viral pneumonia as well as patients with phlegm-heat cough. At present, Jinzhen Oral Liquid has become an important therapeutic aid. In addition, the academic Zhong Nanshan pointed out that Jinzhen Oral Liquid presented good antiviral and anti-inflammatory activities in vitro at the 24th press conference on COVID-19 prevention and control held by the Information Office of Guangdong Provincial Government. The results of modern pharmacology have shown that Jinzhen Oral Liquid presents good inhibitory or antiviral effects on the SARS virus, influenza A virus, respiratory syncytial virus, and Mycoplasma pneumoniae (Xiao et al., 2008; Xiao et al., 2009). Tao et al. (2020) reported that isoglabrolide, glabrolide, ebeiedinone, desoxy-glabrolid-acetate, peimisine, verticinone, imperialine, ussuriedinone, and euchreneone A5 were the active
compounds of Jinzhen Oral Liquid in the treatment of COVID-19. Jinzhen Oral Liquid might inhibit the occurrence and development of the cytokine storm in COVID-19 by regulating the expression of the bromine domain containing protein 2 (Brd2), aminopeptidase N (APN), and ACE2, by interfering with the PI3K-Akt, Jak-STAT, TNF, and MAPK signaling pathways, and by inhibiting viral replication by binding with 3CL protease—thus exerting a preventive or therapeutic effect on COVID-19. In vivo experiments showed that Jinzhen Oral Liquid can alleviate acute lung injury by inhibiting multiple targets and blocking the NF-κB and MAPK signaling pathways (Zong et al., 2018), and it has a good antipyretic effect and is similar to the therapeutic mechanism of Xiyanping Injection (Hong et al., 2021).

Qingkailing Injection is widely used in the treatment of acute pneumonia, upper respiratory tract infection, high fever, and other diseases. Qingkailing Injection has been listed as a recommended drug by the latest version of the Diagnosis and Treatment Protocol for COVID-19 and Prevention Protocol formulated by the Tongji Hospital in Wuhan, Hubei Province. Zhang et al. (2020b) reported that the effects of Qingkailing Injection showed activity against multiple targets and multiple pathways. The active components including acacetin, syrigin, luteolin, kaempferol, quercetin, and apigenin could regulate the apoptosis pathway and the TNF pathway by acting on CASP3, CASP8, FASLG, and other targets, to achieve potential therapeutic effects on COVID-19. Gao et al. (2013) suggested that Qingkailing Injection has an antipyretic effect by decreasing the

![Figure 4](image-url)
expression of 5-HT and the concentration of 4-aminobutyric acid and it can improve the metabolism of amino acids and the urea cycle. Sun et al. (2005) used LPS to cause visceral injury, and the results reflected that Qingkailing Injection had the function of protecting visceral injury as reflected through enhancing the free-radical activity and the inhibition to overoxidation by the results of detecting MDA and SOD levels.

Recent studies have suggested that the aggravation and even deaths caused by viral diseases such as COVID-19 were not only related to pulmonary virus infection, but were also closely associated with the immune dysfunction of the body (Xu et al., 2020d). The studies have shown that Bufei Huoxue Capsule could effectively improve pulmonary fibrosis, reduce the expression of inflammatory factors such as TNF-α and IL6, promote lung tissue repair, and effectively improve the immune response, which also contributes to the recovery of COVID-19 (Ma et al., 2016; Jing et al., 2017). Currently, Bufei Huoxue Capsule has been included in the recommended drug list in the Diagnosis and Treatment Protocol for COVID-19 in Guizhou Province and is mainly used for COVID-19 recovery treatment. Guo et al. (2020a) reported that the beneficial effects of Bufei Huoxue Capsule were not only associated with its antiviral and anti-inflammatory activities, but were also closely related to the regulation of immune function in the treatment of convalescent COVID-19 patients. Its key compounds including quercetin, kaempferol, 7-O-methylisumcranolatol, baicainel, and formononetin target IL6, MAPK8, PTGS2, PTGS1, and NCOA2 to regulate multiple signal pathways of TCM and play a therapeutic role in the recovery period of COVID-19.

Common Pharmacological Actions and Mechanisms

On the basis of reviews and comments on the previous text, we concluded that these 22 recommended CPMs in the treatment of COVID-19 mainly act on anti-inflammatory and immunomodulation and antiviral effects and improve lung injury, antipyretic effect, and organ protection. The results are provided in Table 4 and Figure 3. In addition, we calculated the occurrence times of active ingredients, predicted targets, and signaling pathways predicted by network pharmacology and molecular docking. The results are shown in Figure 4.

Table 4 shows 22 CPMs which all have anti-inflammatory and immunomodulatory effects. Recent studies have suggested that the pathogenic mechanism of SARS-CoV-2 is closely related to inflammatory stimulation and immune dysfunction (Xu et al., 2020c). The immune system responds rapidly after SARS-CoV-2 has infected the body. CD4+ T lymphocytes differentiate rapidly into helper T cells Th1 and Th2, and then, Th1 secretes granulocyte–macrophage colony-stimulating factor (GM-CSF). These cytokines will induce excessive activation of CD14+ and CD16+ monocytes (Zhou et al., 2020b). When the Th1 and Th2 cells and the CD14+ and CD16+ monocytes enter the pulmonary circulation, a significant inflammatory cell infiltration, with the release of proinflammatory cytokines, chemokines, IL1β, IL6, IFN-γ, TNF-α, CCL2, CCL3, and CXCL10, will occur in the lungs, forming a "cytokine storm" causing severe pneumonia and in turn lead to lung injury, acute respiratory distress syndrome (ARDS), and multiple organ failure and even death (Huang et al., 2020a; Zhou Y. X. et al., 2020). The regulatory function of TCM on the immune system is closely related to the production and activity of T cells, B cells, NK cells, macrophages, and cytokines. From the results of COVID-19 clinical research, we can find CPMs can regulate the proportion of lymphocyte and leukocyte, significantly reduce the level of inflammation factors such as CRP, D-dimer, PCT, IL6, IL10, IL17, TNF-α, and IFN-γ, and increase the level of IL4 (Chen et al., 2020c; Qin et al., 2020). Network pharmacology research shows that the mechanism may be related to the IL17 signaling pathway, TNF signaling pathway, and arachidonic acid metabolism pathway. The biological activity of TNF is to promote inflammation, cell survival, and tissue regeneration. TNF can effectively stimulate a large amount of IgG, promote the proliferation of B cells, and activate the adhesion receptors on the surface of endothelial cells and neutrophils (Shen et al., 2020). IL17 is a proinflammatory cytokine mainly secreted by Th17 and other T cells, which exerts a major role in adaptive immunity. The IL17 signaling pathway can reduce the aggregation of macrophages and granulocytes by regulating CXCL2, CCL2, CXCL8, and other chemokines, thus reducing the inflammatory response (Noack and Miossec, 2017; Liu Y. R. et al., 2020). Ren et al. (2020c) concluded that arachidonic acid (AA) metabolism pathway is principally used to synthesize inflammatory cytokines, such as interleukin (IL), interferon (IFN), C-X-C motif chemokine (CXCL), and so on, which directly leads to the cytokine cascade reaction. Therefore, the inhibition of the AA metabolism pathway is beneficial for alleviating the "cytokine storm."

The action mechanism of antiviral drugs is mainly through blocking a certain stage of virus replication and reproduction, such as preventing the virus from entering the host cell (Pawlos et al., 2021), inhibiting the synthesis of the virus (Kumar et al., 2021), and inhibiting the release of the virus (Martin-Sancho et al., 2021), so as to achieve the purpose of inhibiting virus reproduction and controlling viral infection. The antiviral effect of CPMs is through inhibiting the function enzyme of SARS-CoV-2 or binding with the host cell receptor. In the second part of this article, we mentioned that the main targets of anti-SARS-CoV-2 include ACE2 and 3CLpro. ACE2 plays an important role in the process of binding with the virus, while 3CLpro is related to viral transcription and replication. CPMs’ main ingredients kaempferol, quercetin, luteolin, and baicainel have better combinations with Mpro, whileisorhamnetin, stigmastanol, and β-sitosterol can target the ACE2 (Ling et al., 2020; Kong et al., 2020b; Li Y. M. et al., 2020). Kaempferol glycosides are good candidates for 3a channel proteins of coronaviruses (Schwarz et al., 2014). Quercetin was proven to exert an inhibitory effect on PEDV 3Clpro (Li et al., 2020c) and interfere with multiple steps of pathogen virulence viral entry, viral replication, and protein assembly and these therapeutic effects can be enhanced by the CO administration of vitamin C. Quercetin (Colunga et al., 2020). Luteolin has been reported in experimental studies to inhibit viral replication by binding to the spike protein on the surface of the coronavirus and can inhibit 3CLpro, which is required for viral infection (Ling et al., 2004). Liu
et al. (2021) found that baicalein could inhibit SARS-CoV-2 3CLpro activity in vitro with IC50 values of 8.52 µg/ml and 0.39 µM. The effect of isorhamnetin binding to ACE2 was demonstrated by the surface plasmon resonance assay, and it was shown by in vitro virus experiments that isorhamnetin could inhibit SARS-CoV-2 spike pseudotyped virus entering ACE2h cells (Zhan et al., 2021). Anti-inflammatory and antiviral effects of stigmasterol and β-sitosterol were demonstrated in in vitro experimental studies (Petrera et al., 2014; Liao et al., 2018). In addition, kaempferol, quercetin, luteolin, baicalein, and isorhamnetin all belong to flavonoids. Studies have shown that flavonoids could interact with the S1 and S2 sites of MERS-CoV 3CLpro to play a role in antiviral effects (Jo et al., 2019; Ren et al., 2020b).

The SARS-CoV-2 infects humans mainly through the ACE2 receptor and the major invasion site is AT2 cells, resulting in severe lung injury (Kuba et al., 2005). Histopathological changes were also most common in the lungs and blood vessels. The mechanism of lung injury is mainly constituted by two aspects, the production of a variety of inflammatory cytokines by alveolar macrophages and lung epithelial cell activation, such as IL1β, IL2, IL6, IL7, IL8, IL10, tumor necrosis factor-α (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-gamma-induced protein 10 (IP-10) (Zarrilli G et al., 2021). On the other hand, upregulation of endothelial adhesion factor (VCAM, ICAM, VWF, ANG-2, and VEGF) also contributes to lung injury (Polidoro et al., 2020). Treatment of CPMs for COVID-19 is to alleviate excessive inflammatory response in lung tissue mainly by inhibiting the synthesis and release of inflammatory factors. According to the clinical and statistical data, CPMs could cut down the expression of TNF-α, IL1β, MCP-1, and ICAM-1, reduce the recruitment and infiltration of monocyte macrophages, and further reduce the edema of lung tissue to improve lung injury (Fang et al., 2012; Li et al., 2019). In addition, Jinzhen Oral Liquid can block the NF-κB and MAPK signaling pathways to improve lung injury (Zong et al., 2018).

Fever is considered to be one of the main clinical features and judgments of patients with COVID-19. After fever, immune cells activate and release pyrogenic cytokines IL1, IL6, and TNF-α, which then act on essential mediators COX-2 and PGE2 to cause hyperthermia (Ma et al., 2021). The antipyretic mechanism of CPMs is mainly achieved by reducing the cAMP content in fluid, inhibiting the synthesis of PGE2, and reducing the content of central neurotransmitter (Xu et al., 2019). Shufeng Jiedu Capsule and Reduning Injection exert an antipyretic effect through regulating the expression of IL1, IL6, and PGE2 and regulate endogenous pyrogen. The mechanism of antipyretic of Qingkailing Injection is to decrease the expression of 5-HT and the concentration of 4-aminobutyric acid and it can improve the metabolism of amino acids and the urea cycle (Gao et al., 2013). Baicalein, an active ingredient with high frequency in TCM, has a good antipyretic effect. Its mechanism of action is to inhibit arachidonic acid metabolism, COX and LOX, and the secretion and release of nuclear factor and cytokine (Xin, 2013).

Although the novel coronavirus pneumonia is a kind of infectious disease directed at the lungs, studies have shown that it can also damage other organs, such as the heart, nerves, brain, vessels, kidneys, and skin (Hossain et al., 2020). SARS-CoV-2 combined with ACE2 stimulated macrophages and monocytes to release proinflammatory cytokines, including IL6, NF-kB, and TNF-α, leading to inflammation-derived injurious cascades and then to multiple organ failure. Among them, ACE2 plays a key role in inflammation, which may aggravate COVID-19 through the following ways: renin–angiotensin system, including promoting the pathological changes in lung injury and involving inflammatory response (Iwasaki et al., 2021). In addition, its severity is related to the viral load and the regulation of ACE2 receptor (Loganathan et al., 2021). CPMs show high binding affinity with ACE2 playing a role in organ protection, and many active ingredients can repair organ damage. Kaempferol has a protective effect on oxidative stress-induced nerve injury and hepatocyte apoptosis by inhibiting the expression of apoptotic protein (Schwarz et al., 2014). In vitro test showed that baicalein had cardiovascular protective effects such as vasodilation, hypotension, myocardial protection, endothelial cell protection, and antiatherosclerosis (Xin, 2013). The TNF signaling pathway plays a role in the induction of tissue repairs, such as neuronal remyelination, cardiac remodeling, or cartilage regeneration (Noack and Miossec, 2017). The PI3K-Akt signaling pathway has a protective effect on oxidative stress and inflammatory response induced by various pharmacological media, especially playing a key role in the survival, proliferation, and apoptosis of cardiac myocytes (Li et al., 2021).

CONCLUSION AND FUTURE PROSPECTS

Among the many plagues experienced in Chinese history, TCM has played an important role in both early prevention and treatment to control the progression of the disease and improve patient prognosis (Yang, 2020b; Ren J.-l. et al., 2020). Currently, the focus and difficulties in the treatment of COVID-19 concern mainly the more severe and critical cases, which are also the main factors directly affecting mortality. The major purpose of the participation of TCM in the therapy of COVID-19 is to make full use of its advantages in the treatment of mild and moderate COVID-19 patients. For severe or critical COVID-19 patients, TCM can reduce the disease condition and decrease mortality (Yang, 2020b). However, vulnerable patient groups such as the elderly, pregnant and lactating women, infants, and patients with underlying diseases need to be especially cautious when using CPMs. Improper usage of CPMs, such as abuse or misuse, repeated drug use, overdose, drug antagonism, drug incompatibility, drug–drug interactions, and improper syndrome classification, will increase drug-induced risks (Zhang et al., 2020c); for example, when there is a repeated incompatibility in early treatment (such as taking Lianhua Qingwen Capsule and Shuanghuanglian oral liquid simultaneously), this incompatibility will influence the effects of treatment. In addition, for drugs containing ephemda (such as Lianhua Qingwen Capsule and Jinghua Qinggan Granules), doctors should pay attention to the patient’s blood pressure and heart rate.

In vivo experiments showed (Zhang et al., 2021) that Qingfei Paidu decoction can affect the pharmacokinetics of CYP3A substrate drugs through the inactivation of CYP3A, which leads to the risk of disease treatment with CYP3A substrate drugs such as lopinavir.
Moreover, severe COVID-19 patients are prone to experience septic shock, liver and kidney dysfunction, and related underlying diseases which will reduce drug metabolism and clearance rates. For these patients, treatment regimens should avoid the use of drugs with the potential to induce liver and kidney toxicity to avoid the possibility of drug accumulation (Yang, 2020b). At the same time, it should also be noted that respiratory viral diseases, including COVID-19, may present symptoms of critical illness. Although there are corresponding treatment methods among TCM, these still present certain limitations. For these reasons, further exploration of TCM treatment of these diseases and syndromes is needed and we should actively cooperate with Western rescue strategies to improve cure rates and reduce death rates.

All of these 22 TCMs we reviewed are currently widely used clinically, and 10 have been reported in the literature to significantly improve clinical symptoms in patients with COVID-19, and a part of them have also been studied. However, due to the low number of COVID-19 cases in China and the lack of a large number of research subjects, it makes clinical research difficult. We provide a comprehensive analysis of the therapeutic effects and mechanisms of the above Chinese patent medicines, while exploring the mechanism of drug treatment, to provide some basis and clues to the clinical therapeutic effects. But this review has some limitations. At present, understanding of the mechanisms involved in TCM for the treatment of COVID-19 has been mainly achieved through virtual simulations and analyses of potential pharmacological networks and molecular docking studies. The limitations of the network pharmacology and molecular docking screening results are also in function of the complexity of TCM and of its compound composition as well as the complexity and variability of the virus. Thus, studies of composition, predicted targets, and pathways may have some limitations. Further in vivo and in vitro experiments should be carried out to verify the validation of these mechanisms to provide a scientific basis for the TCM treatment of COVID-19 and to provide an experimental basis for antiviral natural medicine research and development.

**AUTHOR CONTRIBUTIONS**

Z-HY, BW, QM, LW, Y-XL, H-FY, Z-XF, H-JC, ZG, H-JW, and B-NZ performed the literature search, selected relevant articles, interpreted data, and wrote the report; Z-HY and BW have contributed equally to this work and share first authorship; FZ was responsible for the entire manuscript; H-DS and Feng L-M designed and supervised this work. All authors have read and approved the final submission.

**FUNDING**

This study was supported by the Hebei North University Youth Fund Project (No. JYT2019010), Tianjin University of Traditional Chinese Medicine Doctoral Student Innovation Program Project (No. ZXYCXLX2019016), and Tianjin Health Commission Integrated Traditional Chinese and Western Medicine Project (No. 2019130).

**REFERENCES**

Bao, L., Shi, Y. J., Geng, Z. H., Sun, J., Zhao, R. H., Du, C. Q., et al. (2020). [Application of Reynanning Mixture in Evaluating Combining Disease with Syndrome of Human Coronavirus Pneumonia with Pestilence Attacking Lung Syndrome]. Zhongguo Zhong Yao Za Zhi 45, 1465–1472. doi:10.19540/j.cnki.cjmm.20200303.401

Cai, N., Li, Y. J., Zhou, G. R., Xin, C., Xie, J., Zhou, H. H., et al. (2020). Theoretical Basis and Effect Characteristics of Andrographolide against COVID-19. Chin. Tradit. Herb. Drugs 51, 1159–1166. doi:10.7501/j.issn.0253-2670.2020.05.0100.1161/strokeaha.119.028010

Cao, C., Cui, Y., Chu, Y. X., Shi, Y. Y., Wu, X. H., Wang, X. Y., et al. (2020). Investigation on Mechanism and Active Components of Shufeng Jiedu Capsule in Treatment of COVID-19 Based on Network Pharmacology and Molecular Docking. Chin. Tradit. Herb. Drugs 51, 2283–2296. doi:10.7501/j.issn.0253-2670.2020.09.002

Centers for Disease Control and Prevention (2020). Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak–United States, December 31, 2019-February 4, 2020. Available at: http://dc.gov/mmwr/volumes/69/wr/mm6905el.htm?s_cid=mm6905el_1 (Accessed February 7, 2020)

Chan, J.-F. W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., et al. (2020). A familial cluster of pneumonia associated with the 2019 Novel Coronavirus (nCoV) in a Family in China: aOnClickListener study of a Family Cluster. The Lancet 395, 514–523. doi:10.1016/S0140-6736(20)30154-9

Chen, J., Wang, W. Q., Shi, C. Y., and Fang, J. G. (2020a). Thoughts on Prevention and Treatment of Coronavirus Disease 2019 (COVID-19) by Traditional Chinese Medicine. Chin. Tradit. Herb. Drugs 51, 1106–1112. doi:10.7501/j.issn.0253-2670.2020.05.003

Chen, L., Ge, G. B., Rong, Y., Fu, W., Zheng, M. Y., Zhao, Y. F., et al. (2020b). Application and Research Progress of Traditional Chinese Medicine in Prevention and Treatment of corona Virus Disease 2019. Acta Univ. Tradit. Med. Sin. Pharmcol. Shanghai. 34 (3), 1–8. doi:10.12688/f1000research.22457.2

Chen, L., Liu, F., Wu, J. H., Song, H. Y., Xia, J. S., Sheng, B., et al. (2020c). Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis. Chin. J. Exp. Tradit. Med. Form., 1–8. doi:10.13422/j.cnki.sfxy.202001628

Chen, R., Wang, T. T., Li, K. L., Shang, R. F., Song, J., and Zhang, J. Q. (2020d). Characteristics and Application of Immune-Regulating and Antiviral Chinese Materia Medica. Chin. Tradit. Herb. Drugs 51 (6), 1412–1426. doi:10.7501/j.issn.0253-2670.2020.06.006

Chen, X., Feng, Y., Shen, X., Pan, G., Fan, G., Gao, X., et al. (2018). Anti-sepsis protection of Xuebijing Injection Is Mediated by Differential Regulation of Pro-and Anti-inflammatory Th17 and T Regulatory Cells in a Murine Model of Polymicrobial Sepsis. J. Ethnopharmacology 211, 358–365. doi:10.1016/j.jep.2017.10.001

Chen, Y. K., Zeng, A., Luo, S. M., Li, C. M., and Lu, Q. (2020e). Study on the Active Compounds and Potential Mechanism of Reduning Injection in Treating Coronavirus Pneumonia. J. Guangdong Pharm. Univ. 36, 381–387.

Chen, W. Y., Liu, C.-P. B., and Wong, K.-Y. (2020f). Prediction of the SARS-CoV-2 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates. F1000Res 9, 129. doi:10.12688/f1000research.22457.2

Cheng, D. Z., Wang, W. J., Li, Y., Wu, X. D., Zhou, B., and Song, Q. Y. (2020). Analysis of Cautative Effect of 51 Patients with Novel Coronavirus Pneumonia Treated with Chinese Medicine Lianhua Qingswen: a Multicentre Retrospective Study. Tianjin. J. Tradit. Chin. Med. 37 (5), 509–516. doi:10.11656/j.issn.1672-1519.2020.05.06
Du, H. T., Wang, P., Ma, Q. Y., Li, N., Ding, J., Sun, T. F., et al. (2020). Preliminary Study on the Effective Components and Mechanism of Huoxiang Zhengqi Decoction in Inhibiting the Replication of Novel Coronavirus. Modernization. Tradit. Chin. Med. Mater. Mater-world. Sci. Tech., 1–7. doi:10.11842/wst.20200221102

Deng, Y. J., Liu, B. W., He, Z. X., Liu, T., Zheng, R. L., Yang, A. D., et al. (2020). Study on Active Compounds from Huoxiang Zhengqi Oral Liquid for Prevention of Coronavirus Disease 2019 (COVID-19) Based on Network Pharmacology and Molecular Docking. Chin. Tradit. Herb. Drugs 51, 1113–1122. doi:10.7501/j.isn.0253-2670.2020.05.004

Du, H. T., Wang, P., Ma, Q. Y., Li, N., Ding, J., Sun, T. F., et al. (2020). Preliminary Study on the Effective Components and Mechanism of Huoxiang Zhengqi Decoction in Inhibiting the Replication of Novel Coronavirus. Modernization. Tradit. Chin. Med. Mater. Mater-world. Sci. Tech., 1–7. doi:10.11842/wst.20200221102

Deng, Y. J., Liu, B. W., He, Z. X., Liu, T., Zheng, R. L., Yang, A. D., et al. (2020). Study on Active Compounds from Huoxiang Zhengqi Oral Liquid for Prevention of Coronavirus Disease 2019 (COVID-19) Based on Network Pharmacology and Molecular Docking. Chin. Tradit. Herb. Drugs 51, 1113–1122. doi:10.7501/j.isn.0253-2670.2020.05.004

Deng, Y. J., Liu, B. W., He, Z. X., Liu, T., Zheng, R. L., Yang, A. D., et al. (2020). Study on Active Compounds from Huoxiang Zhengqi Oral Liquid for Prevention of Coronavirus Disease 2019 (COVID-19) Based on Network Pharmacology and Molecular Docking. Chin. Tradit. Herb. Drugs 51, 1113–1122. doi:10.7501/j.isn.0253-2670.2020.05.004

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet 395 (10223), 497–506. doi:10.1016/S0140-6736(20)30183-5

Huang, J., Li, X. W., Lan, B. Z., Li, J. P., You, D. M., and Zhou, S. (2020a). Clinical Observation on Tanrequei Injection Combined with α-interferon in the Treatment of Confirmed and Suspected Cases of COVID-19. Chin. J. Misdiagn 15 (99), 408–409.

Huang, J. W., An, L. F., Han, X., Li, Q. W., Xue, H., Yang, L., et al. (2020b). The Potential Mechanism of Prevention and Treatment of COVID-19 by Shufeng Jiedu Capsule Was Studied Based on Network Pharmacology. J. Hainan Med. Univ. 26, 814–819. doi:10.13210/j.cnki.jhmu.20200512.003

Huang, Y., Li, J., Xu, K. Y., Wang, D. Q., and Yang, Z. F. (2019). Research Progress on Anti-influenza Effective Components of Isatis Radix. Chin. J. Mod. Appl. Pharm. 36 (20), 2618–2623. doi:10.13487/j.cnki.1007-7693.2019.20.027

Iwasaki, M., Saito, J., Zhao, H., Sakamoto, A., Hirota, K., and Ma, D. (2021). Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Inflammation 44 (1), 13–34. doi:10.1007/s10753-020-01337-3

Jimilham, S. M. Y., Maimaitiming, N. E. M. M. T., Ainiwaer, W. M. E., Maerden, Y. S. F., Muhadasi, N. E., Nuerbiya, N. H. M. T., et al. (2020). Study on the Active Components in the Adjuvant Treatment of Novel Coronavirus Pneumonia (COVID-19) with Jinhuajiang. Qianglan Based on Network Pharmacology and Molecular. J. Chin. Med. Mater. 43, 1275–1283. doi:10.13636/s1001-4454.2020.0406

Jing, Y., Tang, S. H., Jin, J., Cao, R. Q., Wang, Y. Q., Liao, Q., et al. (2017). Influence of Pulmonary Fibrosis in PM2.5 Model Mice with Bufei Huoxue Capsule. World J. Integ. Tradit. West. Med. 12, 774–778.

Jo, S., Kim, H., Kim, S., Shin, D. H., and Kim, M. S. (2019). Characteristics of Flavonoids as Potent MER9-CoS 3C-like Protease Inhibitors. Chem. Biol. Drug Des. 94 (6), 2023–2030. doi:10.1111/cbdd.13604

Kang, L. (2020). Function Characteristics of Xuebijing in the Treatment of COVID-19. Pharmacology. Chin. Chin. Med. Mater. 36, 11–15. doi:10.13412/j.cnki.jyzy20200420.001

Kong, Y., Lin, L. L., Chen, Y., Lai, S., Wu, H. W., and Chen, J. S. (2020a). Observation on Tanreqing Injection Combined with α-interferon in the Treatment of Corona Virus Disease 2019. Chin. J. Mod. Appl. Pharm. 1283. doi:10.1007/s10753-020-01337-3

Kumar, R., Afsar, M., Khandelwal, N., Chander, Y., Riyesh, T., Dedar, R. K., et al. (2020). Experimental Study on Antipyretic Mechanism of Jinzhen Oral Liquid. J. Tradit. Chin. Med. 43, 1160. doi:10.1038/s41564-020-0695-z

Leng, Zh., Rui, H., Hou, W., Feng, Y., Yang, Y., Han, Q., et al. (2020). Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 11 (2), 216–228. doi:10.14336/AD.2020.0228

Li, Y. C., Shen, J. D., Li, J., Wang, R., Jiao, S., and Yi, L. T. (2013). Chronic Treatment with Baicaixin Prevents the Chronic Mild Stress-Induced Depressive-Like Behavior: Involving the Inhibition of Cytokine/Erk-2 in Rat Brain. Prog. Neuropsychopharmacol Biol. Psychiatry 40, 138–143. doi:10.1016/j. jnpb.2012.09.007

Li, P., Wang, T., Fu, S. F., Chang, N. W., and Wang, X. Y. (2016). Clinical Comparison of Shengfu Injection and Shenmai Injection Based on Meta Analysis. Chin. Tradit. Herb. Drugs 47 (16), 2949–2959. doi:10.7501/j.isn.0253-2670.2016.16.030

Li, Q., Yin, J., Ran, Q. S., Yang, Q., Liu, L., Zhao, Z., et al. (2019). [Efficacy and Mechanism of Lianhua Qingwen Capsules(LHQW) on Chemotaxis of Macrophages in Acute Lung Injury (ALI) Animal Model]. Zhongguo Zhong Yao Za Zhi 44 (11), 2317–2323. doi:10.19540/j.cnki.cjcmcm.20190210.001

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. (2020a). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 382 (13), 1199–1207. doi:10.1056/NEJMoa2001316

Li, R. F., Hou, Y. L., Huang, J. C., Pan, W. Q., Ma, Q. H., Shi, Y. X., et al. (2020b). Lianhuaxingwen Exerts Anti-viral and Anti-inflammatory Activity against
Target Proteins in Jinhua Qinggan Granules Treat COVID-19 Based on Network Pharmacology and High-Throughput Molecular Docking Fellowship. Modernization. Travol. Chin. Med. Mater. Mater-world. Sci. Tech. 22, 622–631. doi:10.11842/wst.20200317010

Shi, C. Y., Lin, T., Wang, W. Q., and Fang, J. G. (2020a). Research Summary of Anti-viral Effects of the Forsythia Suspensa. J. Tradit. Chin. Med. 51, 2055–2064. doi:10.7501/journals.issn.1003-0719.202008.0108

Shi, X., Wei, J., Liu, M. Y., Zhou, H. P., Zhu, W. L., et al. (2020b). Study on the Overall Regulation of Xuebijing Injection in Treating COVID-19. Shanghai J. Tradit. Chin. Med. 54, 46–52. doi:10.16305/j.cnki.1007-1334.2020.04.098

Sun, X. D., Yan, Y. H., Chu, W. W., Zhang, Y. T., and Ying, L. J. (2017). Effects of Injection of Reyanning Herb. Drugs 54, 46–52. doi:10.3969/j.cnki.issn.1001-1528.20200318.001

Wang, Y. Z., Cui, X. L., Gao, Y. I., Guo, S. S., Wang, X. K., Huang, Y., et al. (2006). [Antiviruses Effects of Extract from Gardenia.] Zhongguo Zhong Yao Za Zhi 31 (14), 1176–1178. doi:10.3321/j.issn:1001-5302.2006.14.013

World Health Organization (2020). Statement on the Second Meeting of the International Health Regulations (2005). Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). Available at: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) (Accessed April 28, 2020).

World Health Organization (2020). Virtual Press Conference on COVID-19. Available at: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb32b3_2 (Accessed March 27, 2020).

Wu, J. X., Hou, L. L., Liu, C. L., Zhang, L., and Yan, Y. X. (2018). Study on the Pharmacological Action of Antiviral Granule, Chin. J. Vet. Mater. 54 (6), 118–120.

Xiao, W., Xu, L. L., Huo, C. C., Zhang, X. F., Sun, L., Wang, Z. Z., et al. (2008). Experimental Study on the Effect of Zhinhen Oral Liquid on SARS Virus. J. Nanjing Univ. Tradit. Chin. Med. 24, 343–344. doi:10.3969/j.issn:1000-5005.2008.05.019

Xiao, W., Zheng, J. S., Wang, Y., Gao, T., Luo, J., and Wang, Z. (2009). Experimental Study on the Effect of Zhinhen Oral Liquid on Influenza A (H1N1) Virus. Chin. Tradit. Herb. Drugs 40, 1443–1445. doi:10.3321/j.cnki.2023-2670.2009.09.033

Xie, L. H., Wang, J. Q., Lin, X. Y., Qin, T., and Hu, G. H. (2020). Network Pharmacological Analysis and Mechanism Prediction of Xingnaojing Injection in Treatment of Neurological Damage Caused by SARS-CoV-2 Chinese. Chin. Tradit. Herb. Drugs 51, 3211–3222. doi:10.7501/journals.issn.0253-2670.2020.12.013

Xin, W. Y. (2013). Progress in Pharmacological Study and the Underlying Mechanism of Batacine and Baicalin. Chin. J. New Drugs 6, 647–653.

Xu, H. B., Li, P. X., Ji, X. J., Mo, J. H., Huang, Y. F., Fang, C. S., et al. (2020a). Mechanism of Shufeng Jiedu Capsule in the Treatment of Novel Coronavirus Pneumonia Based on Network Pharmacology and Molecular Docking. J. Chin. Med. Mater. 1-1. doi:10.1101/2023-08.09.044

Xu, J. H., Xue, Y., Zhang, Y., and Lu, G. (2020c). Study on Mechanism of Shufeng Jiedu Capsule in the Treatment of Novel Coronavirus Pneumonia Based on Network Pharmacology. Chin. Tradit. Herb. Drugs 51, 2015–2023. doi:10.7501/journals.issn.0253-2670.2020.08.005

Xu, J., and Zhang, Y. (2020b). Traditional Chinese Medicine Treatment of COVID-19. Complement. Therapies Clin. Pract. 39, 101165. doi:10.1016/j.jctcp.2020.10.165

Xu, Z., Shi, L., Wang, Y. J., Zhang, Y. J., Huang, L., Zhang, C., et al. (2020d). A New Coronavirus Associated with Human Respiratory Disease in China. Nature 579 (7799), 265–269. doi:10.1038/s41586-020-2008-3

Xu, Z., Shi, L., Wang, Y. Z., Zhang, J., Huang, L., Zhang, C., et al. (2020e). Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. Lancet Respir. Med. 8 (4), 420–422. doi:10.1016/S2213-2600(20)30076-X

Xu, Z. Y., Li, X. B., Zhang, H. Y., Zhang, S. Y., Yuan, Y. M., Wang, Q., et al. (2019). Study on Antipyretic Effect and its Mechanisms of APN on Lipopolysaccharide-Induced Febrile Rabbts. Travol. Chin. Drug Res. Clin. Pharmacol. 6, 692–694. doi:10.1103/journals.issn.1003-9783.2019.06.009

Yang, H. B., Li, Y. X., Cao, L. M., Feng, X. P., Zhang, J., Jiang, S. Y., et al. (2020a). 11 Cases of New Coronavirus Pneumonia Treated with Modified Decoction of Chinese Herbs Plus Western Medicine. Guangji. J. Tradit. Chin. Med. 43 (3), 1–4. doi:10.3969/journals.issn.1003-0719.2020.03.001

Yang, J. (2020b). Pondering over COVID-19 Prevented and Treated by Traditional Chinese Medicine. J. Nanjing. Univ. Tradit. Chin. Med. 36, 149–151. doi:10.14148/journals.1672-0482.2020.0419

Yang, L. A., and Luo, J. H. (2017). Study on the Effect of Andrographolide Clinical Curative Effect and Cytokines. Jiangxi.
Y. Zhang, C. Y., Li, Z. H., Zhang, S., Wang, W., and Jiang, X. Q. (2020a). Clinical Observation of Rayanming Mixture in Treatment of COVID-19. Chin. J. Exp. Tradit. Med. Form. 26 (12), 2364–2367. doi:10.16448/j.cjtcm.2020.1246

Yao, Y. X., He, Z. X., Liu, X. F., He, Y. Z., Lei, Y., Zhang, S. T., et al. (2020). Potential Material Basis of Kangbingdu Granules for Treatment of Coronavirus Disease 2019 (COVID-19) Based on Network Pharmacology and Molecular Docking Technology. Chin. Tradit. Herb. Drugs 51, 1386–1396. doi:10.7501/j.issn.0253-2670.2020.06.003

Yu, H. Y., Ren, X. H., Qi, X. X., Zuo, Q., and Liu, D. (2020a). Efficacy Study of Arbidol, Qingfei Paidu Decoction, Lianhua Qingwen Capsule, and Jinye Baidu Granules in the Treatment of Mild/Moderate COVID-19 in a Fangcang Shelter Hospital. Pharmacology. Chin. Mater. Med. 36 (6), 2–6. doi:10.13412/j.cnki.zyyl.20201110.005

Yu, S. S. (2019). Research Progress on Chemical Constituents, Pharmacological Effects and Clinical Applications of Jinzhen Oral Liquid as Pediatric Chinese Patent Medicine for Treating Cough and Phlegm. World Sci. Tech-modern. Tradit. Chin. Med. 21 (12), 2759–2763. doi:10.11842/wst.20181008002

Yu, S., Zhu, Y., Xu, J., Yao, G., Zhang, P., Wang, M., et al. (2021b). Glycyrrhizic Acid Exerts Inhibitory Activity against the Spike Protein of SARS-CoV-2. Phytomedicine 85, 153364. doi:10.1016/j.phymed.2020.153364

Yu, Y. R., Lu, P. F., Wang, H. X., and Huang, B. K. (2020c). Prevention and Treatment of COVID-19 with Traditional Chinese Medicine. J. Pharm. Pract. 38 (3), 202–206. doi:10.12206/j.issn.0616-0111.202003098

Zarrilli, G., Angerilli, V., Businello, G., Saraglia, M., Traverso, G., Fortarezza, F., et al. (2021). The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury. Ijms 22 (2), 974. doi:10.3390/ijms22020974

Zeng, X. H., Ma, W. H., and Wang, J. (2020). Effect of Qingfei Paolo Decoction on Clinical Efficacy of COVID-19 Pneumonia with Phlegm Heat Blocking Lung. Med. J. West. Chin. 32 (12), 1799–1801. doi:10.3969/j.issn.1672-3511.2020.12.017

Zhan, Y., Ta, W., Wang, T., Hua, R., Wang, J., Wang, C., et al. (2021). Potential Antiviral Activity of Isorhamnetin against SARS-CoV-2 Spike Pseudotyped Virus In Vitro. Drug Dev. Res. doi:10.1002/ddr.21815

Zhang, C. Y., Li, Z. H., Zhang, S., Wang, W., and Jiang, X. Q. (2020a). Clinical Observation of Xuebijing in the Treatment of COVID-19. Chin. J. Hosp. Pharm. 40, 964–967. doi:10.13286/j.issn.1001-5213.2020.0903

Zhang, D., Zhang, B., Lv, J.-T., Sa, R.-N., Zhang, X.-M., and Lin, Z.-J. (2020b). The Clinical Benefits of Chinese Patent Medicines against COVID-19 Based on Current Evidence. Pharmacol. Res. 157, 104882. doi:10.1016/j.phrs.2020.104882

Zhang, F., Huang, J., Liu, W., Wang, C.-R., Liu, Y.-F., Tu, D.-Z., et al. (2021). Inhibition of Drug-Metabolizing Enzymes by Qingfei Paolo Decoction: Implication of Herb-Drug Interactions in COVID-19 Pharmacotherapy. Food Chem. Toxicol. 149, 111998. doi:10.1016/j.fct.2021.111998

Zhang, H., Liu, Y., and Li, J. S. (2015). Effect on Qingxuan Zhike Particles in the Treatment of Children with Upper Respiratory Infection. Chin. Med. Herald. 30, 132–135.

Zhang, Y. R., Gan, Z. Q., Liu, Z. X., Luo, J., Tang, C., Liu, C., et al. (2020c). Exploring Mechanism of Qingkailing Injection in Treatment of Coronavirus Disease 2019 (COVID-19) Based on Network Pharmacology and Molecular Docking. Chin. Tradit. Herb. Drugs 51, 3201–3210. doi:10.7501/j.issn.0253-2670.2020.12.012

Zhang, Y., and Yang, X. L. (2008). The Difference between Shengmai Injection and Shenmai Injection. J. Pract. Tradit. Chin. Med. 24 (10), 683. doi:10.3969/j.issn.1004-2142.2008.10.066

Zhao, J., Tian, S., Lu, D., Yang, J., Zeng, H., Zhang, F., et al. (2021). Systems Pharmacological Study Illustrates the Immune Regulation, Anti-infection, Anti-inflammation, and Multi-Organ protection Mechanism of Qing-Fei-Dai Ducotion in the Treatment of COVID-19. Phytomedicine 85, 153315. doi:10.1016/j.phymed.2020.153315

Zhao, S. C., Wei, R. L., Xie, Y. M., Wang, I. X., Wang, Q., and Yi, D. H. (2019). [Analysis of Qingkailing Injection in Treatment of Combined Medication Features of 2 147 Cases of Upper Respiratory Tract Infection]. Zhongguxiao Zhong Yao Za Zhi 44 (23), 5207–5216. doi:10.19540/j.cnki.zyyl.20191115.501

Zheng, Y., Liu, Z. Q., Zhu, X. Q., and Wang, B. L. (2020a). To Investigation of the Mechanism of Xuebijing Injection in COVID-19 Treatment Based on Network Pharmacology and Molecular Docking. Chin. J. Comp. Med. 1–13. doi:10.3969/j.issn.1671-7856.2020.07.008

Zheng, Z. W., Ye, W. Q., and Liu, C. F. (2020b). Study on Mechanism of Shuanghuanglian Oral Liquid in Treating Based on Network Pharmacology. J. Chin. Med. Mater. 1–9. doi:10.13683/j.cnki.1001-4454.2020.06.045

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., et al. (2020a). A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 579 (7798), 270–273. doi:10.1038/s41586-020-2012-7

Zhou, X., Lu, Q., Kang, X., Tian, G., Ming, D., Yang, J., et al. (2021). Protective Role of a New Polysaccharide Extracted from Lonicera japonica Thunb in Mice with Ulcerative Colitis Induced by Dextran Sulphate Sodium. Biomed. Res. Int. 2021, 1–9. doi:10.1155/2021/887863

Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., et al. (2020b). Pathogenic T-Cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients. Natl. Sci. Rev. 7, 998–1002. doi:10.1093/nsr/nwa041

Zhou, Y. X., Mei, B., Gao, J. F., and Liu, Z. Y. (2020c). Research Progress of Bufei Huoxue Capsule in the Treatment of Chronic Respiratory Diseases. Chin. J. Tradit. Chin. Med. 32 (12), 2364–2367. doi:10.16448/j.cjtcm.2020.1246

Zong, S. B., Sun, L., Lu, Y. Z., Zhou, J., Wang, Z. Z., and Xiao, W. (2018). Effect of Jinzhens Oral Liquid on NF-Kb, MAPK Signaling Pathway in Mice with LPS-Induced Acute Lung Injury. Chin. J. Exper. Tradit. Med. Form. 24 (9), 155–159. doi:10.13422/j.cnki.syfjx.20180733

Zong, Y., Yao, W. F., Shan, J. J., and Wang, S. C. (2020). Discussion on the Active Compounds of Qingxuan Zhike Granule in Treatment of Pediatric Coronavirus Disease 2019 Based on Network Pharmacology and Molecular Docking Method. World Chin. Med. 15, 477–483. doi:10.3969/j.issn.1673-7202.2020.04.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Wang, Ma, Wang, Lin, Yan, Fan, Chen, Ge, Zhu, Wang, Zhang, Sun and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.